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Abstract
Patient-centered, disease-focused nonprofits are playing an increasingly
prominent role in accelerating the development of new diagnostics, drugs, and
therapies. They are engaging in a variety of complex venture philanthropic
activities as they seek to bridge the "valley of death" gap between basic and
clinical research. Examples of such activities include developing preclinical
research tools, supporting clinical trials infrastructure, and investing in private
biotechnology companies. In this thesis, 1: 1) quantify the financial contribution
of US-based nonprofits to biomedical research and development (R&D) and the
allocation to therapeutic areas; and 2) propose a framework for understanding
the core functions of biomedical venture philanthropies. I find that US-based
nonprofits contributed $3.7 billion to biomedical R&D in 2011, and that within
certain disease areas nonprofit spending is comparable to or exceeds spending
by the National Institutes of Health (NIH). I catalogue nonprofit activities and
place them in a framework of five core functions: bridging gaps, enabling
research, directing pipelines, informing stakeholders, and shaping markets. I
present several case studies via this framework, discuss opportunities, and point
out challenges such as a lack of conflict of interest standards. Methods
included recording and analyzing publically available financial data from over
400 biomedical nonprofits, and conducting a series of in depth interviews with
nonprofit executives and other related professionals.
Thesis Supervisor: Ernst Berndt, PhD
Title: Professor of Applied Economics, MIT
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Introduction
Patient-centered disease nonprofits have a long history of supporting patient
care services, engaging in advocacy, and funding basic science research.
Recently, many disease nonprofits-- whose mission is to see better therapeutics
reach patients as soon as possible-- have begun to increase their focus on
translational research and clinical development, the "bench to bedside" stages
through which insights from basic science are applied toward delivering new
drugs, diagnostics, devices, and medical treatments to patients.
The Cystic Fibrosis Foundation (CFF) achieved one of the landmark early
successes of the venture philanthropic approach. CFF's long term partnership
with a biotech company and Vertex Pharmaceuticals yielded, in 2012, the first
ever Food and Drug Administration (FDA) approved drug that treats the
underlying cause of Cystic Fibrosis. To this end, CFF initiated the drug
development process, provided guiding expertise, helped facilitate clinical trials,
and invested over $100 million in the industry partnership.
In the last decade, there has been a proliferation of venture philanthropic
models aimed at accelerating the development of new therapeutics. The term
'Venture philanthropy' is used in a range of contexts with somewhat varying
meanings. For the purposes of this thesis, a nonprofit is considered to be a
biomedical venture philanthropy if it employs a variety of programs and tactics
to strategically impact the therapeutic development landscape, often including
industry partnerships.
This thesis has two primary objectives:
1) To quantify the financial contribution of nonprofit sector to US
biomedical research and development.
2) To create a framework for understanding how disease-focused venture
philanthropic nonprofits leverage their resources toward impacting
biomedical research and development.
Chapter 1 presents and discusses the quantitative findings. Chapter 2 presents
a framework for biomedical venture philanthropy, and includes case examples
and discussion of future opportunities and challenges. Chapter 2 focuses
primarily on the domestic disease space, but some examples of nonprofit work
in global diseases are drawn in as well. The concluding discussion points to
areas of future research.
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I. Quantification of US Nonprofit Funding for Biomedical
R&D
Summary
The objective of this portion of the study is to quantify nonprofit contributions
and allocations to US biomedical research and development (R&D). This is
carried out by collecting publically available nonprofit data for 2011. I find that
nonprofits contributed $3.7 billion to US biomedical R&D, nearly half of which is
expended by nonprofits employing complex venture philanthropic models.
Nonprofit allocations to therapeutic areas differ moderately from National
Institutes of Health (NIH) allocation in broad categories, while varying more
dramatically for certain specific diseases, ranging from negligible nonprofit
spending to spending more than the NIH outright. Although the overall
percentage contribution of nonprofits to US biomedical R&D is found to be
roughly 3% across all therapeutic areas, there are diseases to which nonprofits--
sometimes a single nonprofit-- devote research budgets comparable to
government or industry.
Literature Review
A literature review of academic journals and industry analyst reports shows that
previous studies accounting for US biomedical research spending have not
focused on a methodological accounting for the nonprofit sector. Estimates of
the nonprofit sector's contribution to medical research have ranged from $1
billion-3 billion. 123 4 1.
Dorsey, for example, estimates foundation giving by multiplying total
philanthropic giving by the percentage of philanthropic giving, based upon the
Foundation Center report. The Foundation Center's report captures a broad
health category including services, access, and advocacy in addition to research
funding.5
There do not appear to be any previous studies quantifying where and how
nonprofit funds are allocated within biomedical research.
'Moses et al estimate of $4B includes private research institutes, which account for at least $ 1B
2 Referred to as "Estimation of Tail" in Appendix B.
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Methodology
Overview
I identified nonprofits active in biomedical research meeting the selection
criteria defined below, with annual expenses over $1 million, and sampled those
remaining with annual expenses in the $50 thousand to $1 million range in
order to estimate the remainder. 2
For nonprofit identification, I used the Guidestar nonprofit database. Guidestar
is a database of US Internal Revenue Service (IRS) Form 990 tax forms filed
annually by nonprofits, as well as supplementary aggregated data.
I recorded the circa 2011 net assets, annual expense, and biomedical R&D
expense for these nonprofits based upon their Form 990s, official websites,
annual reports, grant documentation, and audited financial statements. I
recorded the therapeutic areas targeted by grants, and for large, multi-focus
organizations, when possible, I accounted for the breakdown of their R&D
spending into subprograms. I characterized each organization according to its
level of partnership with industry, and whether it employs a venture
philanthropic model in its approach to biomedical R&D.
Note that this method does not include donations to research made by
individuals out of their personal income. It therefore does not capture total
philanthropic dollars, but rather the total programmatic spending by
incorporated nonprofits.
The resulting spreadsheet is in Appendix B.
Methods Details
Database Search
I searched Guidestar for nonprofits registered with the IRS using the
National Taxonomy of Exempt Entities Core Codes (NTEE-CC) core codes
of H, which designates medical research. Since private foundations are
sometimes multipurpose and not coded as consistently, I cross-
referenced the Foundation Center's lists of top 50 private foundations in
2 Referred to as "Estimation of Tail" in Appendix B.
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medical research and mental health research, though many organizations
on those lists did not substantially meet the selection criteria. 67
Selection Criteria
The selection criteria for nonprofits was:
Inclusion
- Nonprofits established in the US that give grants and allocate other
programmatic expenses toward biomedical R&D in the US and
globally.
Exclusion
- Research institutes or foundations granting exclusively to a
particular institute, hospital, or school.
- Nonprofits that are primarily grant-taking as opposed to grant-
making.
o This excludes private research institutes such as Howard
Hughes Medical Institute, Salk Institute, etc.
- Nonprofits established primarily to distribute government funds.
R&D Accounting
In order to determine how much a given non-profit spent on biomedical
R&D, I used the following guidelines:
- R&D includes grants paid directly to researchers as well as directed
R&D projects such as creating a biobank.
- R&D excludes advocacy, healthcare access, logistics, and patient
support and services.
-When possible for larger, multi-focus nonprofits, the list of awarded
grants was analyzed in order to more precisely delineate biomedical
R&D from other expenses, and in order to account for the allocation
of grants into therapeutic areas.
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Net Assets
Net assets were recorded for organizations significantly devoted toward
biomedical research.
-Organizations with R&D Expense/Total Expense ratios above 15%
were considered significantly devoted to biomedical research.
Circa 2011
Nonprofit budgets are reported from 2011 financial reports when
available (vast majority), and otherwise the most recent documentation
available was used (none earlier than 2009).
In the case of private foundations with highly sporadic annual granting
and/or reporting, total numbers and/or therapeutic allocation were
calculated over a five year average.
Error Reduction
Reducing double-counting
- Grant lists from private foundations and several of the largest
nonprofits were checked when possible to discount grants made to
other charities already included on the list.
For highly international organizations (eg Wellcome) registered with
501c3 status in the US but arguably based elsewhere, only those grants
were counted for which the grantee is a US based researcher.
Estimation and Error
Nonprofits employ inconsistent methods in expense reporting.
- The biomedical R&D expense numbers recorded may or may not
include R&D overhead, depending on the reporting practices of the
nonprofit.
- In a handful of cases, estimation is required in order to record the
biomedical R&D expense portion of total expenses.
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- Private foundations often have more opaque reporting, necessitating
estimation based upon the available information.
- Private foundation grants were varyingly recorded as grants paid out
or as grants allocated in 2011, depending on availability of reporting.
- Private foundations that do not donate a significant portion of their
funds to biomedical research are difficult to locate via database
searches, therefore this category is underreported.
- The exclusion criteria require judgment on borderline organizations.
o For example, the decision to include Ludwig Institute but
exclude Amyotrophic Lateral Sclerosis Therapy Development
Institute based upon the exclusion of private research
institutes. Or, for example, the differentiation of US vs
international nonprofits.
- Characterization of R&D model and industry partnerships was based
upon published information.
- For some large multi-focus foundations, accounting for every grant
by topic/ therapeutic area was not always possible, and such dollars
were assigned to a "General" category.
Results and Discussion
Total Nonprofit Biomedical Spending
401 nonprofits were identified in total, including the sample set of
organizations with annual expenses under $1 million (see Methods). 72 private
foundations and 67 venture philanthropies were identified.
This study finds that nonprofits spent a total of $3.7 billion on biomedical R&D
in 2011. These nonprofits-- many of which engage in a variety of activities
other than biomedical R&D such as advocacy, education, access, patient
services, or in the case of some private family foundations granting to other
programmatic areas-- had total expenses of $13.3 billion. The net assets of
nonprofits primarily dedicated to medical granting summed to $52.3 billion.
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Figure 1.1
Total Nonprofit Biomedical Research Net Assets And Expenses, 2011
(in millions)
Net Assets Expenses Biomedical R&D
Nonprofit Total $52,284 $13,337 $3,670
Nonprofit landscape
Figure 1.2 reports the top 25 largest nonprofits identified in this study. The top
25 organizations contribute approximately 60% of the total nonprofit biomedical
R&D spending.
Top 25 Largest Biomedical Research Non-Profits
by 2011 Medical R&D Expense
2 Cancer Public American Cancer Society $ 1,374,385,000 $ 964,970,000 $ 148,468,000
Juvenile Diabetes Research
3 Diabetes (Type 1) Public Foundation $ 48,031,000 S 203,785,000 $ 128,264,000 /
4 Heart Disease Public American Heart Association S 652,988,000 $ 616,339,000 S 120,718,000
Ludwig Institute of Cancer
5 Cancer Public Research $ 4,401,000 $ 113,059,000 $ 99,565,000 /
Huntington's Private6 Disease operating CHDI Foundation $ 40945000 $ 108395000 $ 93 106000 .
General: Genomnics;
7 Stem Cell Research;
IBD; Alhelimers Private
Global Health;8 Infectious Diseases
9 Breast Cancer Public
Diabetes (Type 1);
10 Crohns & IBD;
Cardiovascular Private
Leuketnia &
11 Lymphoma Public
12 General Private
13 Parkinson Public
14 Pediatric Cancer
15 AIDS
16 Cystic Fibrosis
17 General
18 Diabetes
19 Autism
20 Multiple Sclerosis
21 Tuberculosis
22 Aging
23 Dystrophy
Ienerai, Uver
24 disease
25 Neonatal Health
Public
Public
Public
Private
Public
Private
Public
Public
Broad Foundation
PATH Vaccine Solutions
Helmsley Charitable Trust
Leukemia& Lymphoma Society
Wallace H. Coulter Foundation
Michael . Fox foundation
National Childhood Cancer
Foundation (aka Cure Search)
Internationtal AIDS Vaccine
Initiative
Cystic Fibrosis Foundation
Foundation for the NIH
American Diabetes Associatalon
Simons Foundation
MS Society/Fast Forward
Aeras Global TB Vaccine
Foundation
Priate Ellison Medical Foundation
Public Muscular Dystrophy Association
Private WM Keck Foundation
Public March of Dimes
S 1,926,000,000 $ 170,452,000 S 87,833,000
$ 126,817,000 $ 37,227,000 $ 37,227,000 V
$ 193,219,000 S 408,978,000 $ 75,302,000
S 3,947,443,000 S 221,894,000 S 74,050,000
$$
$
123,45,000
289,253,000
21,122,000
$ 299,075,000
S 75,160,000
$ 67,917,000
$ 10,803,000 $ 67,530,000
S 70,907,000
$ 175,449,000
$ 73,000,000
$ 84,623,000
S 1,603,560,000
S 90,123,000
$ 38,210,000
$16,838,000
S 13,357,000
$ 83,316,000
5 313,763,000
$ 56,000,000
5 199,999,000
$ 148,000,000
$ 213,777,000
$ 47,796,000
$40,907,000
5 175,594,000
$ 71,985,000/
$ 68,268,000
$ 62,016,000
S 61,101,000
$ 59,902,000 .
$ 55,000,000 .
$ 50,000,000
S 44,218,000
$ 45,000,000
$ 40,257,000 .
$ 39,504,000 V
$38,965,000
$ 38,126,000 V
S 1,167,429,000 $ 52,754,000 $ 36,000,000
$ 54,000,000 5 206,093,000 5 30,835,000
I 1
Figure 1.2
Figure 1.3 shows the wealth distribution of nonprofits, in terms of annual R&D
spending. Anecdotally, the nonprofit landscape is often described as highly
fragmented. 89 While this study did not capture one-off donations made by
individuals or small family foundations, the $3.7 billion documented here is
fairly concentrated amongst the top 50 organizations.
14 nonprofits were identified that spent over $50 million annually on biomedical
R&D. By comparison, biotech companies spent $50 million on average in R&D in
2011, while pharmaceutical companies had R&D budgets in the multibillions 10.
In the second chapter of this thesis, I will discuss the ways in which nonprofits
seek to leverage their budgets to fill translation gaps left by industry and
government.
Figure 1.3
Non-Profit Wealth Distribution
(by 2011 Biomedical R&D expense)
<$1M
x
~1100
Orgs
$100M-$500M
x
3 Orgs
In addition to size, it is useful to describe nonprofit landscape according to
several parameters: 1) Is the nonprofit a private, operating private, or public
foundation? 2) Does it employ a more traditional or a more venture
philanthropic model in supporting biomedical R&D?
Traditional versus venture models fall on a spectrum, and sometimes judgment
is involved in assigning an organization to one category or the other. In a purely
traditional model, a nonprofit typically issues a request for grant proposals in
the disease of interest, perhaps with some loosely targeted strategic categories,
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and uses an external advisory board to review the applications and award the
grant budget. In a venture philanthropy model, the organization evaluates the
wider therapeutics development landscape and seeks to fill gaps through a
variety of programmatic mechanisms usually including several of: traditional
grants, highly targeted grants, contract research, industry partnership,
investment in companies, facilitating IP, development of precompetitive shared
tools, and/or reduction of clinical trial costs.
Figures 1. 4 and 1.5 provide the spending breakdown and financial anatomy
according to these nonprofit categories. Because the Bill and Melinda Gates
Foundation is so large, it is shown separately to give a clearer view of the overall
statistics.
Figure 1.4
Traditional v Venture
Nonrrofit
Financial Totals, 2011
(in millions)
OTraditional
Model
*Gates
Foundation
U Complex
Venture
Model (w/
out Gates)
Public v Private Nonprofit
Financial Toals, 2011
(in millions)
$60,000
$50,000
$40,000
$30,000
$20,000
$10, 000
$0
eO
* Public
Nonprofits
" Gates
Foundation
" Private
Nonprofits
(w/out
Gates)
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Primary Reserve Ratios (Net Assets/Expense)
Primary
Reserve
Ratio (years)
Primary
Reserve
Ratio (years)
Private Nonprofits 7.0 Complex Venture Model 0.3
(w/out Gates) (w/out Gates)
Gates Foundation 8.8 Gates Foundation 8.8
Public Nonprofits 0.8 Traditional Model 3.5
The majority of private foundations are single family foundations with large net
assets, sometimes designed to endow legacy giving. A rapid accumulation of net
assets may occur when the funder has a major taxable increase in wealth, such
as the sale of a company. The vast majority of these foundations give research
grants or capital improvement grants to universities, private research institutes,
and hospitals. A couple of notable private foundations are operating
foundations, such as Gates Foundation and CHDI Foundation (Huntington's).
Private operating foundations are treated differently under IRS code,11 but the
feature most relevant to this study is that such organizations, in addition to
being grant-makers, spend significant funds on their own operational activities
toward carrying out their mission. Like private non-operating foundations, these
nonprofits tend to draw the majority of their funding from a single donor, or
occasionally several. Although private foundations have more stringent formal
legal requirements, they are often more strategically opaque and more
unilaterally controlled than public foundations, since they do not need to market
themselves to a wide group of donors.
Comparing the primary reserve ratios, I find that venture philanthropies are
breaking the traditional nonprofit mold, in terms of financial anatomy.
Traditionally, disease nonprofits have been structured along the lines of private
foundations, in terms of primary reserve ratio, defined as net assets divided by
expense. The standard practice was to ensure longevity of the organization by
accumulating a substantial asset base. As seen in Figure 1.5, venture
philanthropic disease foundations have a much lower primary reserve ratio than
do traditional foundations, similar to what is advisable for a small and midsized
business. Venture philanthropies (excepting Gates Foundation) maintain on
average enough assets to roughly maintain a quarter year of expense in absence
of revenue. This finding fits with the narrative that venture philanthropies and
their donors expect an organization to do everything it can as soon as possible
to find a cure, rather than saving for later, and that donors expect the nonprofit
to operate somewhat like a virtual biotech company including maintaining a
14
Figure 1.5
similar level of risk of going out of business if they don't perform well and fail to
attract revenue.
Relative Contribution to Total US R&D
Nonprofits contributed 3% of total US biomedical R&D spending in 2011. Figure
1.6 shows the relative contributions of philanthropic foundations;
universities and research institutes; government; and industry.
Figure 1.6
US Biomedical Research Funding, 201112,13
Universities Nonprofit
(Institutional 3%
Funds) &
Private
Research
Institutes
10%
Values other than Nonprofit derived from Dorseyet et al., JAMA; and Research!America.
Although nonprofits constitute 3% of overall spending and have a collective R&D
budget that is 12% that of the NIH, there are therapeutic areas in which
nonprofits spend similar amounts or more, in absolute dollars, than does the
NIH. An example of this is Type 1 Diabetes: nonprofits spent over $200 Million
in 2011, while the NIH spent $150 Million. The biggest Type 1 Diabetes
nonprofit on its own spent $128M, nearly as much as the NIH. Nonprofit
allocation in therapeutic areas will be explored further in a subsequent section.
Figure 1.7 compares nonprofit R&D spending to Venture Capital (VC)
investment. The portion of venture philanthropic funds invested directly in
companies was estimated based upon data collected for the top 20 venture
philanthropic funds.
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Figure 1.7
Venture Capital vs. Nonprofit Investment in Biomedical Sciences, 2011
$9,000 mVenture Philanthropies: Direct
grants/investments in$8,000 companies
$7,000
Venture Philanthropies:$6,000 General R&D Spending (Grants,
$5,000 contract research, clinical
networks, biobanks, etc)$4,000 N...... . *Traditional Non-Profits:
$3,000 Grants
$2,000
$1,000 
-VCs: Investments in biotech
$.. and medical device companies
Venture Capital Nonprofits
Source of VC figures: PricewaterhouseCoopers and the National Venture Capital Association,
Moneytree Report, 2011.
Nonprofits approach VCs in total annual spending in biotech, and amount to
about half of the total VC spending on biotech and medical devices combined.14
However, nearly half of nonprofit dollars are spent via a traditional academic
grant giving model. A relatively small fraction of venture philanthropic dollars
are invested directly in companies in a manner directly analogous to VCs, in
exchange for equity or contractual return on investment. Biomedical program
related investments (PRIs) are still a relatively new practice, in which nonprofits
are still testing the waters.
Nonprofit Allocation to Therapeutic Areas and Comparison to NIH
Having taken a birds eye look at how much nonprofits are spending as a whole,
the next natural questions are: Where are nonprofits spending their R&D dollars,
and how? The remainder of this chapter will look at where, and the next chapter
will look at how.
I was able to account for the therapeutic area of 85% of the nonprofit spending
documented in this study. Unattributed "General" spending arose from lack of
available information, the estimate of the tail, and general capital improvements
or research funding grants made to multifocal research institutions, most often
by private foundations with broad medical missions.
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Figure 1.8 documents the allocation of nonprofit funds across a selection of
therapeutic areas, and compares this allocation with that of the NIH.
The categories shown are a subset of the NIH's 235 standard selected categories
for reporting its year to year spending. 15 Note that the NIH's reporting
categories are not a comprehensive list of diseases with funded research.
Following the NIH's method of reporting therapeutic allocation, the individual
categories are not mutually exclusive, and a given grant can be counted in
multiple categories. For example, a grant to study breast cancer would be
counted both in the "Breast Cancer" and the "Cancer " categories. The sum of
spending across categories exceeds and does not reflect the total spending of
nonprofits or NIH.
While every NIH grant is individually tagged with weighted relevant categorical
keywords 16, this study accounted for nonprofit spending at the programmatic
level, and so nonprofit allocations have relatively less precision. Keeping in
mind the various methodological limitations, several salient features arise from
the results and are discussed below.
[Figure 1.8 on next page]
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Figure 1.8 Nonprofit R&D by Therapeutic Category, vs NIH (in millions)
Nonprofits
allocate
proportionally
more
Nonprofits &
NIH allocate
similarly
NIH allocates
proportionally
more
NP Total /NIH Total NIH Total Spending NonprofitTotal Spending Biggest Single Nonprofit
Huntingtons 169% $ 56 1$ 95 $ 93
Multiple Myeloma 150% $ 11 $ 17 $ 17
Diabetes (Type 1) 134% 1 150 201 $ 128
Brain Cancer 134% s 280 0 374 $ 25
Muscular Dystrophy 105% $ 75 1$ 78 $ 30
Cystic Fibrosis 70% 1$ 79 1$ 55 $ 55
Rett Syndrome 59% $ 12 $ 7 $ 4
Tourette Syndrome 58% $ 5 $ 3 $ 3
Parkinson 53% 5 151 1$ 80 $ 62
Tuberculosis 49% 5 209 1$ 103 $ 40
Autoimmune Disease 46% 869 U 397 $ 128
Leukemia & Lymphoma 43% 5 199 I$ 85 $ 72
Autism 42% $ 169 $ 71 $ 45
Inflammatory Bowel Disease (IBD) 40% 1$ 113 1 $ 45 $ 24
Multiple Sclerosis 38% 1$ 122 | $ 46 $ 40
Chronic Fatigue Syndrome 36% $ 6 $ 2 $ 1
Atai 3% $ 13 $ 4 $ 3
ALS 3% $ 44 $ 13 $ 8
Batten Disease 29% $ 4 $ 2 $ 1
Rare Diseases 26% $ 57913 $ 128inl Crd Injury 25% $ 38 20 r 8
NeurodegenerativeDisease 25% 1,622 401 $ 62
Lunga 23% 1,278 294 $ 55
Influenza 22% 272 $ 59 $ 59
Infectious Diseases 21% 6s 820 $ 675
Neuroebronatosis 21% $ 23 $ 5 $ 5
Diabetes 21% 1,076 221 $ 128
MyotOn11c DPyWtopy 19% $9 $2 $ 2
Myesthen a Gravis 18% $ 9 $ 2 $ 1
N Lemann-Pick - 15% $ 3 $ 0 $ 0
Cancer - 15% 715 $ 792 $ 148
Lung Cancer - 14% 221 "$ 30 $ 23
HIV/AIDS - 13% .i S4 $ 401 $ 261
Dyston a - 13% $ 13 $ 2 $ 1
Beain Disease - 12% 16 1$ 462 $ 93
Macular Degeneration - 12% $ 105 $ 13 $ 3
Charcot-Marle-Tooth Disease - 12% $ 13 $ 2 $ 1
Lupus - 11% 106 $ 12 $ 7
Breast Cancer 11% i715 $ 76 $ 73
Tuberous Sc6erosis 10% $ 20 $ 2 $ 2
Alzi mers 9% 448 $ 41 $ 25
Heart./Cardlo - 8% 2,049 166 $ 121
Scleroderma 8% $ 25 $ 2 $ 4
Digestive Diseases 7% $ 1,698 1$ 127 $ 34
Down Syndrome 7% $ 20 $ 1 $ 1
Tabacco/SmokIng 7% $ 362 $ 26 $ 23
pancreaticCancer 6% $ 112 $ 7 $ 13
Vulvodynla 6% $ 2 $ 0.1 $ 0.1
Ovarian Cancer 6% $ 138 $ 8 $ 6
Mental Illness 6% $ 2,275 $ 127 $ 45
Epilepsy 5% 4 152 $ 8 $ 4
Eye Disease 5% $ 831 $ 40 $ 16
Atai H Telanglectasla 4% $ 13 $ 0.5 $ 0.3
Cerebral Pa0y 3% $ 23 $ 1 $ 1
Obesity 3% $ 8 $ 28 $ 10
Migraine 3% $ 16 $ 1 $ 0.4
Polycystic Kidney Disease 2% $ 42 $ 1 $ 1
Coss Anemia 2% $ 20 $ 0 $ 0.4
Substance Abuse 2% 1,623 $ 29 $ 23
Sudden Infant Death Syndrome 2% $ 23 $ OA $ 0.4
Lyme Disease 0.5% $ 28 $ 0.2 $ 0.2
Dental/Oral & Cranlofacdal 0.5% $501 $3 $3
Colo-Rectal Cancer 0% $313 $ 0.2 $0.2
Hepatisis 0% $208 $ 0.1 $0.1
Sickle Cell 0% $65 $ 0.01 $ 0.01
Food Safety 0% $ 287 $ - $ -
Sleep Research 0% 1$ 232 $ - $-
OsteoporosIs 0% 1$ 179 $ - $ -
Blodenfese 0% $ 1,803 $ - $-
Anorexis 0% $ 11 $ - $-
Pagets 0% $ 1 $ - $-
Fetal Alcohol Syndrome 0% $ 36 $ - $ -
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Nonprofit vs NIH Allocation to Broad Categories
The biomedical research funding from the nonprofit sector is 12% that of the
NIH, whose 2011 budget was $31 billion, including $16.5 billion in external
research project grants. 17 While nonprofits and NIH allocate moderately
differently across major categories, within those major categories allocation to
specific diseases can differ to a great extent. There are multiple therapeutic
areas in which nonprofits outspend the NIH outright, and others in which
nonprofits have negligible funding activity.
Looking at the major categories from Figure
allocation. Figure 1.9 shows nonprofit v NIH
NIH spends greater than 500M.
Figure 1.9
Nonprofit vs NIH Allocation
(NIH Budaet >
1.8, I find a moderate difference in
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Rare Diseases
The NIH defines rare diseases as those effecting under 200,000 people in
the US. Diseases which are highly prevalent in the world but rare in the US
are counted as a rare disease, and therefore disproportionate nonprofit
spending on infectious diseases and global health elevates nonprofit
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allocation in this category. Even factoring out malaria and tuberculosis, it
appears that nonprofits still spend proportionally more on diseases that
are globally rare.
Autoimmune Disease
Nonprofit's high allocation in this category is largely a result of spending
on Type 1 Diabetes, Multiple Sclerosis, and Irritable Bowel Syndrome.
Note that despite nonprofits' lower allocation to Digestive Diseases,
nonprofits allocate significantly higher budget percentage to IBD than
does the NIH.
Infectious Disease
Nonprofits disproportional spending is largely a result of the Gates
Foundation.
Substance Abuse
Nonprofits allocate proportionally less than the NIH. The majority of
nonprofits with substance abuse related missions provide rehabilitation
services to addicts. Many such organizations indirectly contribute to
research by supporting or operating the rehabilitation facilities at which
clinical studies are carried out; however that is not captured in this study.
Obesity
Similar to substance abuse, nonprofits identified as primarily engaging in
obesity tended to focus exclusively or nearly exclusively on funding or
implementing obesity reduction programs.
Nonprofit vs NIH Allocation to Narrow Disease Categories
Within the broader categories, allocations to specific diseases differ more
dramatically. At the bottom of Figure 1.8 are several diseases to which
nonprofits allocate negligible funds including: Colorectal cancer, Hepatatis B,
sickle cell anemia, osteoporosis, Pagets, and Lyme. Moving up there are a
handful of diseases to which NIH allocates proportionally significantly more than
nonprofits including: Sudden Infant Death Syndrome, Cooley's Anemia,
Polycystic Kidney Disease, Migraine, Ataxia Telangiectasia and Cerebral Palsy.
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For some of these diseases, such as Cerebral Palsy, there are very active and
large nonprofits that focus nearly exclusively on education, advocacy, and
support services. For other of these diseases, such as Hepatitis, a strong
nonprofit presence is entirely lacking.
At the other end of the spectrum are the therapeutic areas in which nonprofits
allocate proportionally more than the NIH. For several diseases, the nonprofit
budget is greater than the NIH budget in absolute terms including:
Huntington's, Multiple Myeloma, Type 1 Diabetes, Brain Cancer, and Muscular
Dystrophy. In the cases of Huntington's and Multiple Myeloma, the single largest
nonprofit expends more than the NIH, and for Type 1 Diabetes, the single
largest nonprofit spends nearly as much as NIH.
Additionally there are a host diseases in which nonprofits spending is greater
than 1/3 of the NIH's spending, including Cystic Fibrosis, Rett Syndrome,
Tourette Syndrome, Parkinson's, Tuberculosis, Leukemia & Lymphoma, Autism,
Inflammatory Bowel Disease, and Multiple Sclerosis, and Chronic Fatigue
Syndrome.
Nonprofit and NIH funding allocation is not entirely independent of each other.
Staff from several rare disease nonprofits stated in interviews that prior to their
seeding of academic research, the NIH received far fewer grants in their disease
area and therefore funded it less. Analysis of if and how nonprofit funding has
led to increased NIH funding over time would make an interesting topic for a
future study.
Determinants of Nonprofit Allocation
What determines nonprofit allocation? Why does nonprofit spending diverge so
drastically from NIH spending for certain diseases? Considering that nonprofit
dollars are not budgeted centrally like the NIH, these are complex questions and
a thorough treatment is beyond the scope of this study. However, I can offer
some speculative impressions.
Strong organizations arise from strong, mission motivated stakeholders
including founders, leaders, and donors. A strong disease nonprofit may be
more likely to arise with a combination of four factors: curability, heartstrings,
neglect, and fortuity.
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Curability
People are motivated by the perception of possibility that a therapy will
completely reverse an illness. Many large public disease nonprofits use
the word "cure" ambitiously in their tagline, including Juvenile Diabetes
Research Foundation (JDRF), Cystic Fibrosis Foundation, Michael J. Fox
Foundation, Multiple Myeloma Research Foundation, Susan B. Komen, and
National Childhood Cancer Foundation.
According to JDRF management, many of their biggest donors state their
goal of finding cure before their children go to college18. For diseases for
which a notion of "cure" is more elusive, nonprofits may not employ the
idea of game-changing therapies in their marketing, and may focus their
efforts primarily on patient services. Examples include Downs Syndrome
and Cerebral Palsy.
Heartstrings
Many disease nonprofits are founded, promoted and funded by parents
of children afflicted with the disease. People who passionately rededicate
their money, time, and/or expertise toward tirelessly working on a
disease nonprofit are often motivated by their love for their children,
family, or themselves.
The diseases that pulls strongest at heartstrings may be ones such as
those that strike children or thriving young people, leading to a gradual
and excruciating deterioration of their health. Examples are Muscular
Dystrophies, Huntington's Disease, and Cystic Fibrosis. Parents may be
less motivated to rededicate decades of their lives and or savings toward
preventing Sudden Infant Death Syndrome, because doing so will not
bring back their infant and may not feel like the most obvious means of
honoring their brief life. Another example of diseases which might lack a
strong heartstrings factor may be Hepatitis C, which perhaps due to
stigma, people feel less compelled to publically champion.
Neglect
Those with loved ones suffering from rare diseases may feel a heightened
sense of duty to take action if they perceive that the disease is not
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currently receiving adequate attention from the biomedical community.
Parents who help drive ultra rare childhood disease organizations often
report having felt a galvanizing sense of anger along with a call to action
upon learning that there were few new therapies on the horizon, and that
their child's disease was not a commercial priority. In global health,
combatting neglect is a central impetus behind organizations such as the
Gates Foundation.
Fortuity
For a given rare disease -- most of which receive under $20 million in
NIH funding-- a single high net worth philanthropist can instantly raise a
disease nonprofit to the level of prominence higher than the NIH. A
strong nonprofit is likely to arise when a person with a bounty of
resources-- whether that be money, connections, or high level
professional pharmaceutical experience-- becomes impassioned about
curing a disease.
The CHDI Foundation singlehandedly gives Huntington's disease an
exceptional nonprofit presence, and it is funded by a single, impassioned
high net worth individual affected by the Huntington gene. 19 Why does
multiple myeloma, a rare cancer that strikes people at a median age of
6920, have such a extraordinary disease nonprofit when other similar rare
cancers do not? Kathy Giusti, a visionary pharmaceutical executive, was
diagnosed with the disease and proceeded to found and build the
Multiple Myeloma Research Foundation. 21
Sergey Brin, co-founder of Google, has donated $125 million over the
past four years to the Michael J Fox Foundation after learning that he had
a genetic risk factor for Parkinson's. 22 The growing popularity of personal
genetic testing could alter the landscape of donorship, by motivating
people to support research before they or their family are affected, and it
could lengthen the timeframes within which people judge a disease's
curability.
In Chapter 2 of this thesis, I identify and discuss some of the strategies that
nonprofits are employing to leverage their resources toward accelerating the
development of new therapies.
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11. A Framework for Biomedical Venture Philanthropy
Introduction
In the context of rising clinical trial costs, increasing attention to rare diseases,
and the movement of pharmaceutical companies toward a partnered research
and development model, the role of nonprofits across stages of therapeutic
development is becoming more prominent. Inspired by success cases such as
the Cystic Fibrosis Foundation, many foundations are adopting biomedical
venture philanthropy models.
As reported in the quantitative chapter of this thesis, nearly half of nonprofit
research spending comes from biomedical venture philanthropies. Some of
these organizations, such as the Juvenile Diabetes Research Foundation (JDRF),
have substantial budgets and even outspend the NIH, whereas others, such as
Jonah's Just Begun, are severely resource constrained. Because disease
nonprofits are positioned to play a different role than either the government or
industry, they can leverage their spending by operating strategically at the
intersection of science, patients, caregivers, regulators, and industry toward the
sole goal of delivering improved treatment options.
The remainder of this chapter looks at the range of activities being undertaken
by biomedical venture philanthropies, and proposes a framework for
understanding these activities in terms of core functions.
Methods
Information for this section was collected from academic journals, media
articles, materials published by nonprofits, presentations at the 2012 Faster
Cures Conference: Partnering For Cures, and a series of one-on-one interviews.
In depth interviews were conducted with managers at 10 nonprofits, a
pharmaceutical company, and a law firm. The nonprofits ranged in size from
under $100 thousand in annual expenses, to over $120 million and included:
Name Title Organization Organization Type
Kenneth Fasman, chief Science Officer Adelson Foundation Nonprofit: IBD, Melanoma,
PhD for Medical Research Neural Repair
Lynn Schenk Director Biogen Idec Pharmaceutical company
Robi Blumenstein President CHDI Nonprofit: Huntington's
24
Simon Noble, PhD Director, Scientific
Communications
CHDI Nonprofit: Huntington's
Susan Rudieger Director of Development CMTA Nonprofit: Charcot-Marie-
Tooth
Michael Kelly, PhD Chief Scientific Officer Cure Duchenne Nonprofit: Duchenne MD
Beth Arnold Partner Foley & Hoag Law Firm
Julia Greenstein, Vice President, Cure Therapies JDRF Nonprofit: Diabetes Type 1
PhD
Jill Wood Founder & Treasurer Jonah's Just Begun Nonprofit: Sanfilippo Type C
Jane Larkindale, Director of Translational MDA Nonprofit: Muscular
PhD Research Dystrophy
Sonal Das, PhD Senior Associate Director, MJFF Nonprofit: Parkinson's
Research Programs
Skip Irving Director MJFF Nonprofit: Parkinson's
Louise M Perkins, Chief Scientific Officer MMRF Nonprofit: MultiplePhD Myeloma
Carolyn Hoban, Director of Translational MMRF Nonprofit: Multiple
PhD Research Myeloma
The interviewees were selected in order to gain a better understanding of some
of the most active and well-regarded nonprofits and their partners. In this
sense, the thesis draws from an intentionally biased sample in order to support
the objective of proposing a framework for venture philanthropic activity.
Background
Nonprofits are Uniquely Positioned
Disease-focused nonprofits are uniquely positioned to play a different role than
academia, government or industry. As nonprofits, they are mission oriented,
highly motivated, and patient centered.
Mission oriented
Nonprofits are the only player in the biomedical R&D landscape
steadfastly committed to advancing treatments for their disease of
interest. Government grants go largely toward academic researchers who
seek to produce new basic knowledge in their fields, while companies
and investors redirect their pipelines according to economics and seek to
maximize shareholder value.
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Motivated
Nonprofits are typically set up by people affected by the disease: parents,
siblings, friends of patients, and patients themselves. They are racing for
a cure, and failing that, wanting to fight for a meaningful legacy for their
lost loved one. While the biomedical landscape has no shortage of
ambitious and dedicated researchers and executives who are driven to
succeed, it is hard to match the undeterrably urgent, and inspiring,
motivation of a parent trying to save their child.
Patient Centered
The majority of disease nonprofits are funded and driven by patient
communities. Among resourced organizations, nonprofits are well
positioned to be entrusted by patients to represent their interests.
The unique position of nonprofits allows them to address all stages of research
and development, and to bridge gaps and remove roadblocks on the pathway to
better treatments. For example, nonprofits may play a coordinating role
amongst stakeholders, and may translate between academia and industry. Todd
Sherer, President of Michael J Fox Foundation, explains, "We have a focused,
longer view. We put patients front and center in our decision- making all the
time, whereas government and private-sector funders cannot always do that.
This informs our sense of urgency and our willingness to take greater risks. We
have a different risk/ benefit balance than do academics, regulators, or
industry."23
The Evolving Role of US Disease Nonprofits
We are not your grandmother's charity. We survey the scientific
and clinical landscape ourselves, develop an agenda to
strategically deploy our dollars, and then work to ensure we are
making the smartest use of our money."
-Louis Degennaro, Chief Mission Officer, Leukemia and
Lymphoma Society 23
Patient-centered, disease-focused nonprofits have played a significant role in
the US since the early 20th century. Traditionally, disease nonprofits supported
a combination of patient education, community services, public advocacy, and
research. Research support was predominantly geared toward basic research in
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academic labs, and administered through peer-reviewed, researcher-initiated
grants.
One of the oldest, largest and most widely known disease focused nonprofits is
the March of Dimes, which was founded in 1938 by President Franklin
Roosevelt, with the goal of eradicating polio. Between 1938 and 1955 when the
polio vaccine was launched, the March of Dimes (at the time known as the
National Foundation for Infantile Paralysis) grew to over 3000 local volunteer-
run local chapters. It raised and spent hundreds of millions of dollars for polio
patient care services, and played a significant role in funding and supporting the
controversial testing of the polio vaccine.24 25 The organization has since
refocused its mission on decreasing birth defects, and engages in patient
education and services, advocacy, and academic research grants. The March of
Dimes' role in pushing forward the polio vaccine might be considered one of the
earliest cases of a nonprofit driving clinical development, however in the wider
nonprofit space and within the organization itself, such tactics would remain an
exception rather than rule for years to come.
In the 1980's and 90's, AIDS advocacy catalyzed increased funding and attention
given to HIV/AIDS, and achieved paradigmatic changes in regulatory policy. The
nonprofit AIDS Coalition to Unleash Power (ACT UP) organized highly visible and
effective protests in the late 1980s, such as shutting down Wall Street and
picketing at the FDA, and they matched their attention-grabbing displays with a
sophisticated agenda. Meanwhile, the Aaron Diamond Foundation heavily
invested in AIDS research at a time when the US government was still hesitating.
Foundation funded labs are credited with the basic discoveries that underlie
today's HIV treatment regime. Among the complaints of ACT UP were that too
little attention was being given to treatments for opportunistic infections that
afflict those with AIDS, the lack of representation of women and minorities in
clinical trials, and the lack of access to life saving drugs that were caught in a
glacial approval process. Activists organized a protest called "Storm the NIH" in
1990, which resulted in patient-driven clinical trial designs. This paved the way
for one of the lasting regulatory legacies of the AIDS movement: the FDA's
codification of Accelerated Approval procedures, designed to give patients
access to life saving drugs earlier in the clinical trials process. 26
In the early 2000's, disease nonprofits began to fundamentally change and
expand their strategies for supporting biomedical research by breaking down
the silos between nonprofit and industry. This transformation was prompted by
a combination of frustration with status quo and recognition of new
opportunities.
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With the rising cost and longer time frames for drug development 27, and the
seemingly expanding "valley of death" financing gap for translational research,
many analysts and media commentators were painting doom and gloom for the
pharmaceutical industry, while a few were suggesting that the industry could
evolve into a new era of networked research and development. In the mean
time, patient centered disease nonprofits that had been pouring money for
decades into basic research to further mottos such as "race for the cure" became
frustrated that few new treatments were progressing toward clinical
development. If the race was for the cure, the finish line was nowhere in sight.
So, they started thinking about how they could pick up the pace.
Venture philanthropic principles were coming into vogue in the greater
nonprofit arena. Loosely this meant adopting aspects of private sector
management principles, working on more integrated capacity building, and
thinking through a lens of maximizing social return on capital analogous to how
a venture capitalist would view private financial return. Pioneered by the Ford
Foundation in the 1970s, more foundations were making Program Related
Investments (PRIs), which allows nonprofits to do things such as grant low cost
loans, and is a tool used both to support financial sustainability and to interface
with commercial markets. 28
Simultaneously, the Human Genome Project was enabling rapid discoveries of
the genetic causes of disease and making it easier to identify drug targets. The
advent of high throughput screening was offering an accessible route through
the early stages of drug discovery. These technologies paved the clearest path
for the development of treatments for genetic diseases, and especially for single
gene disorders. Most genetic diseases are rare, and many single gene disorders
are ultra rare. Fortuitously, a series of regulatory reforms, starting with the
Orphan Drug Act of 1983, were making it quicker and more commercially
rewarding for companies to include rare and previously untreated disease in
their pipelines. According to the National Organization of Rare Diseases, there
are roughly 7000 rare diseases, defined as those that affect under 200,000
people in the US. Of these, 80 percent of rare diseases are genetic, and only 5%
have FDA approved treatments. 29 in this climate of unmet potential, rare disease
patient communities now saw a greater opportunity to attract academia and
eventually industry interest to their cause.
Nonprofits in the rare domestic disease and neglected global diseases space
such as the Bill and Melinda Gates Foundation, the Cystic Fibrosis Foundation,
and the Michael J Fox Foundation led the way in innovating new tools and
tactics. In order to bridge the valley of death, they focused not just on basic
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research, but also translational research and clinical trials. Strategically, they
sought to evaluate the entire therapeutic landscape in order to bridge gaps and
derisk therapeutic candidates with a goal of attracting deep pocketed
commercial investors.
Figure 2.1
Venture Philanthropies and The Drug Development Financing Gap
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Since 2000, many disease nonprofits have adopted venture philanthropic
models. Venture philanthropies design and manage support for a complex set
of activities ranging from establishing clinical trial networks to partnering with
for profit companies. Further regulatory reforms such as the FDA's Breakthrough
Therapy designation have expanded opportunities for accelerated approvals.
The spectrum of biomedical nonprofits now ranges from those such as the
American Heart Association that administer mostly traditional academic
research grants, to organizations such as JDRF that are divided fairly evenly
between funding academic and early translational research, to organizations
such as CHDI Foundation (Huntington's disease) that consider themselves to be
virtual, non-profit biotech companies. 30
Figure 2.2 shows some of ways that venture philanthropies can contribute
across the stages of drug development.
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Figure 2.2
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Nonprofits that are more active across the stages of drug development tend to
-look different, structurally. As their programs multiply, they may require deeper
organizational structure and increased overhead, relying less on occasional
volunteer advisor boards and more on internal staff with science and industry
expertise and management experience. As discussed in Chapter 1, venture
philanthropies tend to maintain net asset to expense ratios that more closely
resemble small businesses than endowed foundations, embodying the urgency
demanded by donors.
The Cystic Fibrosis Foundation produced one of the first success stories in
domestic biomedical venture philanthropy, and can serve as an illustration of
some of the mechanisms listed above. Its narrative has been well documented in
the popular media and is the subject of a Harvard Business School case study.
Nearly every nonprofit manager interviewed for this thesis referenced CFF's
success in describing the goals of their own program.
30
Fund
- Academic
grants
Provide Tools
* Collaborative
platforms
" Tissue banks
Advocate for
government
funding
Establish FDA
status
Eg orphan
Cystic Fibrosis Foundation: Venture Philanthropic Pioneers Who Struck Gold
The Cystic Fibrosis Foundation (CFF) was founded in 1955 by a group of parents
whose children had Cystic Fibrosis (CF), with the mission of improving the
quality of life of patients and funding research toward a cure. Cystic Fibrosis is a
rare genetic disorder affecting approximately 30,000 people in the US. The
disease degrades the lungs and other organs, and patients typically survive in
the range of their teens to late thirties.31
By 1990, CFF was the leading CF organization in US with 250,00 volunteers, 550
employees, 80 charters and branch offices, and 115 care centers throughout the
US. They had invested $594 million to research and care centers for patients.
Earlier diagnosis and better care-- such as physical therapy to loosen lung
mucus, and antibiotic regimens to treat lung infections-- greatly extended life
expectancy. CFF also funded the 1989 discovery of defective genes that cause
CF. 32
As of 1998, after a failed attempt at gene therapy, there were still no drugs
developed to treat underlying cause of disease. Recognizing that CF was not an
attractive investment for industry, CFF President Robert Beall embarked upon a
new strategy of derisking therapies by both advancing translational science and
subsidizing companies. To initiate the Therapeutics Development Program,
Beall sought to fund a high throughput screening company that would be willing
to apply its technological platform to CF. Beall recalls having had trouble getting
screening companies to return his call, presumably since he was representing a
nonprofit.33
Beall managed to forge a set of pioneering biotech partnerships, including one
with an early stage company called Aurora Biosciences. CFF pledged $46.9
million in milestone based fees to Aurora for their application of drug screening
technologies to CF. The parties agreed upon a co-commercialization
arrangement on any resulting CF candidate drugs, which included a revenue
share on marketed products. At the time, this was the largest drug
development contract ever awarded by a nonprofit to a for-profit. 34
Aurora was acquired by Vertex Pharmaceuticals in 2001. Vertex was interested
in Aurora for its drug screening technology, and Vertex management
deliberated over whether to continue with or terminate Aurora's partnership
with CFF. Swayed by CFF's commitment of supplying substantial funding to
what otherwise would not have been an attractive disease, Vertex maintained
the partnership. 35
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CFF immediately reached out to its most active parent fundraisers to launch a
massive fund raising campaign to enable the partnership. Joe and Kathy
O'Donell, whose son Joey had recently died of CF, launched the Joey Fund in his
memory, and raised nearly $50 million. 36
In sum, CFF contributed $75 million to Vertex's clinical development of
Kalydeco, 37 which in 2012 became first FDA approved drug that treats the
underlying cause of disease, for a portion of people afflicted with cystic fibrosis.
The FDA approved Kalydeco within an exceptionally fast three months of
receiving its application, in part due to expertise provided by CFF and its
partners. 38
Eric Olsen, who heads CF research at Vertex, has said that interacting with CFF
gave his team a purposed sense of focus: "We were like a racehorse with
blinders on. The goal was getting a medicine to patients. Everything we did, we
put through that lens. [...] Nothing is more powerful than when it is your own
kid, your brother, your sister, and it keeps focus on getting to something real,
even if it takes 20 years." 39
While Kalydeco was initially approved to treat a 4% subset of CFF patients, the
share will likely soon be expanded to 15%. Further, a combination trial for
Kalydeco and VX-809 is in Phase 3 and shows promise for treating 50% of CFF
patients. The FDA has awarded this combination trial with Breakthrough
Therapy designation, which enables the study to be conducted in a hastened,
six month time frame. 40
Josh Boger, who founded Vertex and served as CEO through 2009, credits CFF:
"Simply and clearly put: without the Cystic Fibrosis Foundation funding, Vertex
could not be in CF. Without their innovative funding model, we might be
enthusiastic and passionate about transforming the treatment paradigm for
patients with this genetic disease. But we wouldn't be able to act on that
passion." 41
Vertex reported $99 million in second quarter 2013 net product revenues from
Kalydec.42 Billed at over 300K a year, the drug is usually covered by private
insurance and if not, it is subject to Vertex's charitable patient access program.
Overall, the case of Kalydico has been hailed in the popular media as a landmark
success for rare diseases and for nonprofit-industry partnership. Some in the
popular media have criticized the high price of the drug, while others maintain it
is the price required to make such drugs for rare diseases worthwhile to
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pharmaceutical companies. Prompted in part by rising concerns about conflict
of interest 43, CFF sold its royalty stream to an undisclosed company for $157
million in 2012.44
CFF is reinvesting all proceeds from Kalydico into further advancing CFF
therapies. Beall is committed to seeking therapies for all CFF patients, down to
the smallest genetic subsets: "We're not going to settle for less than one
hundred percent of patients." 45 CFF currently is invested in a broad clinical
development pipeline, including a $58 million partnership with Pfizer aimed at
finding new drug candidates.46
CFF's successes have helped spur hope in venture philanthropic models
amongst patients, donors, and leaders of other disease nonprofits. Like the
1840s pioneers in covered wagons attempting to cross Death Valley for the
promise of gold, nonprofits with venture philanthropic models are attempting to
cross the "Valley of Death" toward the promise of therapeutic success.
The next section of this thesis surveys the methods and models being used by
biomedical venture philanthropies operating in varying disease types and under
a range of resource constraints, and organizes their activities into a framework.
A Biomedical Venture Philanthropy Framework
Framework Overview
Figure 2.3
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Figure 2.3 proposes a framework for disease nonprofit models in R&D. It
depicts how nonprofits apply Resources toward Functions. Nonprofit Resources
consist of:
- Leadership. Capable, motivated, management.
- Knowledge. Of the science, patients, market, regulatory and multi-
stakeholder landscape of the disease.
- Networks. Of patients, first and foremost. Then, doctors, researchers,
investors, other nonprofits, and industry.
- Funds. To spend on functional activities and on building more resources.
Functions categorize the activities toward which nonprofits leverage their
resources. Nonprofits can allocate their resources amongst four primary
Functions are: Enable, Direct, Inform, Shape, and the 5th Function, Bridge, is a
critical set of activities present within and between the other categories.
- Enable researchers with tools and infrastructure, and attract more
researchers to the field.
- Direct pipelines with active, targeted, support for selected therapeutics.
- Inform stakeholders about the disease landscape, advocate, and influence
decisions.
- Shape market forces with instruments that augment demand or compensate
for market inefficiencies.
Figures 2.4-2.7 detail the four Functions by cataloguing the kinds of activities
that fall within each category.
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As depicted in Figure 2.3, these functions are overlapping and linked with each
other. The Bridge function can be observed throughout, connecting
stakeholders and filling gaps. Nonprofits form bridges within and between
academia, industry, clinicians, researchers, investors, government, other
nonprofits, and patients. For example, they bridge companies to each other by
facilitating preclinical data sharing, and academia to industry by optimizing
preclinical research tools. They bridge clinicians together by supporting clinical
trial infrastructure, and bridge patients with clinical trials through patient
registries and recruitment support. William Schmidt, CEO of Foundation
Fighting Blindness, said "We can be viewed as a 'matchmaker of science."' 47
In depth explanations of each the four core functions and case examples of
functional activities comprise the next several sections of this chapter.
Enable
"A portion of our work is devoted to making the whole field
of Huntington's disease more attractive to researchers and
industry. We derisk the entire landscape in order to attract
new companies."
- Robi Blumenstein, President, CHDI
(Source: Interview)
Enabling research is about attracting increased participation in the field by
creating accessible R&D infrastructure. It is about empowering academia and
industry to pursue their own paths into the disease landscape. An example of
an enabling activity is reducing clinical trial costs. This makes clinical
development and commercialization quicker, easier, and cheaper. Another
example of an enabling activity is supporting tissue banks and data repositories.
Creating research enabling tools and infrastructure is also fundamentally a
bridging activity, as it brings together the research community so that it can
harness its collective power in a way that benefits each member individually.
And it bridges transitional gaps between academics and industry, for example,
by working to optimize academically identified biomarkers for clinical study use.
This section will describe three categories of enablers: basic grants, research
enabling tools, and reduction of clinical trial costs.
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Basic Grants
The simplest way to empower researchers is by distributing capital. While not
every flavor of grant falls into the "Enable" category, several do such as
"traditional" peer-reviewed requests for proposals and human capital grants.
More targeted forms of grants will be discussed later in the "Direct" category.
For traditional nonprofits, basic grants represent the majority of the research
support. For venture philanthropies, the percent of the budget that goes toward
traditional grants varies depending upon the disease and upon the strategy of
the nonprofit. For example, the Juvenile Diabetes Research Foundation (JDRF)
spends roughly half of its research budget on basic grants, whereas the CHDI
Foundation has no open call for proposals.
Traditional grant programs tend to follow an awards process similar to that of
the NIH and other larger granting institutions, in which applications are
reviewed and selected by an advisory committee. Nonprofits have the ability to
carry out this process more leanly and quickly, and most strive to leverage their
grants beyond being purely additive to the government funding pool. For
example, nonprofits may seek to award riskier seed grants to novel ideas that
lack sufficient data to earn government funding. This is the purpose behind the
JDRF's Innovative Grants. JDRF awards Innovative Grants to ideas that have the
potential to be "groundbreaking," while "preliminary data is not required in the
proposal."48
The Adelson Medical Research Foundation uses its grant mechanism to
encourage interdisciplinary collaboration. They do not solicit proposals from
individual researchers. Instead, the Foundation invites scientists from different
laboratories and universities to physical and virtual meetings, where they
"identify key challenges in finding treatments for diseases"49 and then have the
opportunity to apply for relatively large grants for collaborative proposals that
involve working together and sharing data toward a common goal. 50
Human capital grants are another form of enabling grant that many nonprofits
have traditionally offered. For example, JDRF offers Postdoctoral Fellowship
grants and Career Development Awards to attract promising researchers who
are early in their careers to undertake Diabetes Type 1 research.
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Research Enabling Tools
"Researchers need laboratory tools to develop and test potential drugs, yet too
often, these tools are expensive or altogether unavailable to the research
community at large," reads the Michael J Fox Foundation (MJFF) website. 51 MJFF
has a particularly robust program for providing research enabling tools, and
serves as a demonstrative example case.
MJFF developed or facilitates access to laboratory reagents and other tools. The
MJFF website connects researchers and tools vendors to provide a low to no cost
one stop shopping spot for Parkinson's Disease (PD) researchers.
MJFF currently makes 205 preclinical research tools available to scientists. Since
they announced their first antibody in 2010, they have distributed their tools
more than 8,500 times.5 2
Analogous to an Amazon for PD research tools, researchers can easily search for
and order tools, as well apply for tools grants and consult with MJFF science
staff. Figure 2.8 is a screenshot of the MJFF tools catalogue.
Figure 2.8 MJFF Online Tools Catalogue
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The three year old research tools program started as a series of discrete
responses to issues that were observed to be slowing down the research
community, and has since been brought together into a coherent program.
MJFF identifies the need for new tools by observing problems raised at research
conferences and consulting with science and industry advisors in order to
prioritize those needs. s3
Currently, the MJFF research tools program includes: reagents, research models,
biospecimens and data, genetics resources, and digital tools. Along with the
biospecimens and data, MJFF facilitated a precompetitive consortia amongst
drug companies. The details below are drawn from interviews with MJFF
management and from MJFFs published materials.
Reagents
MJFF provides access to low cost proteins, monoclonal antibodies, assays,
DNA plasmids, and viral vectors-- a toolset broadly useful in diagnostics
and drug discovery and in the examination of PD genetic pathways. Some
of these products are developed via contract research by the Foundation,
while other reagents are already commercially available but are brought
under the MJFF research tools umbrella. MJFF has so far developed 17
antibodies, 1 assay, 145 plasmids, one protein, and 8 viral vectors.
MJFF began its reagents program in 2009, after observing that problems
with commercially available antibodies, such as inconsistences and lack
of validation, were impeding the ability of researchers to build upon each
other's work. In response, MJFF decided to contract the development of
high quality, monoclonal antibodies.
MJFF then reached out to its network of academic scientists to test and
prioritize candidate antibodies in order to determine which ones would
be included in the catalogue. MJFF refers to this collaborative effort as a
Community Validation Model 54, and has since institutionalized the model
as part of its tools creation process.
In reference to the LLRK2 encoded protein implicated in PD onset,
Andrew West, Assistant Professor at University of Alabama, recalled: "One
of the complaints that people generally had in the field was that this was
just going to be one of those proteins that there just wasn't going to be a
good antibody for." Thanks to the antibodies produced by MJFF, West
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says that researchers now, "see very good results and quite uniform
results ... the field no longer can say that we don't have good antibodies
to work with." 55
Research Models
MJFF has supported the development of its own mouse and rabbit
models, and is working with partners on an immortalized cell line. MJFF's
transgenic and knockout animal models are available to order through its
website, and MJFF gives full access to data and tissues from its animal
models studies. In total the MJFF catalogue offers 17 animal models,
which includes several that it developed.
The research models program began as a way of addressing several
problems observed in the PD research community: 1) Animal models
developed at Universities, often with MJFF support, were intermediated by
Technology Licensing offices and were difficult for small biotech
companies to license and afford. 2) Likewise biotech labs that create and
protect their own models were not available to the greater research
community. 3) The proliferation of models not only was inefficient, but
led to a problem in experiment replicability, which was slowing progress
and deterring pharmaceutical companies from picking up on academic
and biotech research.
Biospecimens & Data, Pre-Competitive Consortium
MJFF supports the development of and access to biospecimen
repositories and their associated clinical data. MJFF has brought together
and standardized multiple international natural history studies and
biobanks, some of which had been previously inaccessible.
MJFF initiated a landmark study called the Parkinson Progression Marker
Initiative, which is an observational, multi-center study with 1,910
enrolled subjects. To help fund this study, MJFF organized a consortium
of industry players, nonprofits, and private individuals. Industry funders
benefited from input in design study and early access to the results which
are ultimately made publically available.
The biospecimens and data initiative enables a variety of research, but
was primarily motivated by the need for better diagnostic biomarkers of
disease progression. Such biomarkers can serve as endpoints that reduce
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the duration and cost of therapeutic clinical trials. Clinical Trials related
to Central Nervous System have some of the longest clinical trial times of
any therapeutic area, and take 35% longer to complete. 56 To address
this, MJFF convened a task force composed of leading PD clinicians and
academic and industry scientists to develop a framework for prioritizing
biomarker needs. MJFF also noted that the academic researchers who
initially discover biomarkers have little motivation to optimize them for
use in industry. MJFF bridges this gap between basic research and
development by contracting the optimization of potential biomarkers. 57
Genetics Resources
MJFF helped launch a publically accessible database, containing a
comprehensive, unbiased and regularly updated field synopsis of PD
genetic association studies. This database is funded and maintained in
partnership with the Max Planck Institute and the Alzheimer Research
Forum.
Digital Tools
MJFF publishes components for developing smartphone applications that
measure PD disease progression. They offer a collection platform as well
as a data set collected from Parkinson and non Parkinson subjects. In
conjunction, MJFF also held a contest for the development of data
analysis algorithms, which resulted in 630 data set downloads in 21
countries, and 20 applicants from leading institutions.
Other nonprofits that provide research enabling tools include the Myelin Repair
Foundation, Accelerated Cure for MS, Chordoma Foundation, Multiple Myeloma
Research Foundation, National Psoriasis Foundation, Bonnie J. Addario Lung
Cancer Foundation, and CHDI Foundation.
CHDI observed the same problem that MJFF had observed with animal models:
that preclinical tools developed at universities were too often mired in licensing
logistics and fees. CHDI, MJFF and other nonprofits now seek to prevent this
from occurring by including when possible a clause in their academic grant
mechanisms requiring that the research tools developed under the grant be
made freely available to the research community.
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Collaborative Tools
Several important examples of collaborative tools were covered in the previous
section including pre-competitive consortia, shared genetics databases, and
intellectual property sharing frameworks.
Reduction of Clinical Trials Costs
By reducing the time, effort, and costs associated with conducting clinical trials,
a nonprofit can derisk clinical development in its disease area, and accelerate
the time to market for therapeutics. This task is especially important in the
context of overall rising clinical trial costs in the past several decades. 58 Over
half of the cost of developing a new drug can be attributed to clinical trials. 59
Recruiting and retaining clinical trial patients can potentially cost more and
consume more time than any other aspect of the clinical trial process.
According to the Tufts Center for the Study of Drug Development, nine out of
ten clinical trials worldwide eventually meet their enrollment goals, but in order
to reach enrollment, drug developers typically need to double their original
timeline. 60 Development launch delays in Phase Ill can cost an estimated $12-17
million per month. 61
A fundamental lever with which nonprofits facilitate clinical trials is patient
mobilization: patient registries, matching patients with opportunities to
participate in clinical trials and helping them to follow through on enrollment.
For ultra rare disease organizations, finding the affected patient population is a
challenging task that can take years of effort. Many patients with ultra rare
diseases do not receive a proper diagnosis, and when they do, health privacy
regulations often prevent them from being located through publically available
databases. With the rise of social networking and internet discussion boards,
searching for and connecting with the patient community is a task that can be
undertaken by even the most resource constrained organizations. Bringing
together affected families also has the benefit of helping to increase collective
grassroots fundraising.
The Progeria Foundation has located 100 affected children since it was founded
in 2009, and recently launched a "Find the other 150" campaign to seek out the
statistically expected number of children with Progeria who remain unidentified.
Progeria is an ultra rare genetic disease causing children to "age" rapidly and
typically die from heart failure in their teens. In support of the first ever clinical
44
trial to treat Progeria, using a repurposed Merck owned cancer drug, the
Progeria Foundation (annual budget $1.2 M62) raised funds to pay for "clinical
tests, translators, staff, travel, food and lodging expenses for the 28 families
from 16 countries who came to Boston every four months for two years." 63
Another key way of reducing clinical trial costs is by identifying markers of
disease progression that can serve as surrogate clinical endpoints and reduce
the duration and cost of clinical trials. This is the purpose of the MJFF's
Parkinson Progression Marker Initiative described previously, a large
observational clinical study supported by a consortium of industry partners that
seeks to enable biomarker identification and address the long and expensive
nature of PD trials.
For an ultra rare disease like Progeria, clinical endpoints such as weight gain or
arterial stiffness can be established through a relatively small and brief Natural
History Study designed to observe the course of disease progression. In such
cases, it could be that the disease has not yet been sufficiently systematically
observed before, and an observational study is a necessary step toward clinical
trials.
For diseases in which clinical studies may require large cohorts and multiple
centers, nonprofits can help to develop and improve the trial infrastructure. The
Multiple Myeloma Research Foundation (MMRF), whose annual budget is around
$25 million, has taken a comprehensive approach to significantly increase the
efficiency of clinical studies in Multiple Myeloma by establishing a clinical trial
network. The innovative Multiple Myeloma Research Consortium (MMRC) was the
first clinical network that brought together leading academic centers and
industry solely dedicated to advancing Phase I and 11 trials.
MMRC is comprised of sixteen member institutions. Its goals are to facilitate
both biobanking and clinical studies. MMRC increases the efficiency of its
clinical trials using a variety of practices including:
- A system for on-site management to expedite protocol, budget, and
internal review board approval processes
- Centralized contracting across the member institutions
- Quality assurance of sponsors' protocols
-A trial platform for MMRC-sponsored investigators which enables them to
conduct multicenter trials with the same quality as company-sponsored
trials
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The MMRC has facilitated more than thirty Phase 1 and Phase 2 clinical trials
involving more than twenty investigational agents. Eight MMRC drug studies are
currently in Phase 3. MMRF President Kathy Giusti reports that " MMRC's clinical
trial's open ~60% faster than the industry standard in oncology and enrollment
is completed 12% faster ...]."64
Safi Bahcall, President and CEO of Synta Pharmaceuticals, said "Working with the
MMRF and the MMRC provides both the resources and the access to top-tier
investigators and clinical trial sites that can be of tremendous help in
accelerating the potential of novel therapies, such as ganetespib, to benefit
patients with multiple myeloma." 65
Direct
"A key aspect of what we do is derisking Parkinson disease
research by placing bets on ideas and therapies..." 67
-Todd Sherer, CEO, Michael J Fox Foundation
Directing research involves taking an active role in steering the course of
research. It can involve advancing and placing bets on novel approaches to
studying or treating an illness, identifying and carrying out drug development
tasks, or investing in and derisking a portfolio of specific therapeutic
candidates. For resource constrained organizations, such a portfolio might only
contain one or two therapeutic candidates.
The line between enabling versus directing science can be fuzzy, but at their
poles they stem from different philosophies toward science. Allan Tobin, a
senior scientific adviser for CHDI, explained "Ninety-five per cent of science
works on the principle that the best thing to do is to let good scientists follow
their noses. But this is a different attitude. We think we can direct the science."
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Targeted Grants
Targeted grants are requests for proposals on specific topics or problems that
the nonprofit has deemed are important in furthering its scientific strategy.
In addition to JDRF's more "traditional" grant program, which was discussed in
the "Enable" section of this chapter, JDRF allocates approximately 30% of its
grant budget to targeted research. 69 JDRF calls for proposals that address a set
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of priorities and objectives that JDRF has judged to be "critical gaps and
challenges and potential breakthroughs in Type 1 diabetes research "70. JDRF
administers most of its targeted grants through its Strategic Research
Agreements (SRA) program. Applicants for SRAs are required to consult with a
PhD member of JDRF's science strategy team and define achievement
milestones. The SRA timeframe is typically up to three years, but there is no
advertised maximum budget or timeline, and funding can be flexible based
upon project progress.
JDRF's internal expert staff leads the process of crafting its scientific strategy,
with multi-stakeholder input. In 2007, the JDRF board of directors made a
decision to increase in house science expertise, and the organization has since
hired over 20 PhD's. Prior to that, all JDRF grant programs were decided upon
by committees of outside advisors. To determine their targeted research
strategy, JDRF experts establish a set of priorities with input and feedback from
academic and industry thought leaders, and from their science and business
advisory boards. JDRF also solicits input from lay people, by asking donors and
members of JDRF what kind of progress they would most like to see, and what,
to them, constitutes a "cure."
An example of one of JDRF's targeted research goals is: A replenishable
encapsulated beta cell product capable of delivering insulin independence for at
least 1 year with no chronic immunosuppression therapy."71 Toward this goal,
JDRF seeks research proposals that address a set of priorities including:
- Evaluating existing alginate technologies for clinical utility
- Developing novel biomaterials encapsulation methods
- Macro-encapsulation device development
- Large animal testing of technologies that have achieved robust small animal
proof-of-principle
- Mechanisms to improve durability of encapsulated beta cell sources
SRAs are JDRF's primary mechanism for directing science activity. They put
relatively less funds into company investments, and as of 2012, JDRF has not
contracted research. 72
Other top organizations that have targeted grant programs include MJFF and
MMRF.
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Industry Investments and Partnership
Nonprofits are increasingly working directly with companies to advance clinical
development. Three varieties of partnerships are contract research, collaborative
partnerships, and direct investment.
Contract Research
In contract research, the nonprofit pays a fee to outsource preclinical or clinical
research work to a company on a contract basis. The company produces the
agreed upon deliverables for the nonprofit. In order to make use of contract
research, the nonprofit must have its own clear scientific objective.
For example, MJFF contracted the creation of a Parkinson's animal model. 73
CHDI, the largest Huntington's nonprofit, has contracted drug screening and
most stages of "hit to lead" early drug development. 74
Collaborative Partnership
Collaborative partnerships are agreements between companies and nonprofits,
to which either or both commit funds, but which does not involve direct grants
or investments from the foundation into the company.
For example, CHDI approached Pfizer with a hypothesis that a Viagra like
compound could be effective against Huntington's Disease, which is a rare
genetic neurodegenerative disorder. CHDI offered to screen Pfizers compounds
and carry out preclinical drug development, and to hand the results to Pfizer at
no cost and no obligation to them. As a result, Pfizer is planning clinical trials
for a drug called MP-10 in 2014.75
Pre competitive consortia, which have been described previously, might also fall
under the category of collaborative partnerships, as the nonprofit facilitates the
consortia to which companies subscribe.
Direct Investment
Venture philanthropies can fund biotechnology and pharmaceutical companies
directly in order to advance their mission of clinical development. In some cases
48
nonprofits make grants to companies, without demanding any return on
investment. However, in most cases nonprofits feel that if they invest a large
sum to further commercially lucrative research, they should then recoup some
amount of funding to plough back into their mission.
Several examples illustrate the range of objectives with which nonprofits invest
in the commercial sector:
Seed Risky Companies
The nonprofit provides seed funding to derisk the early work of a
company so that, if successful, it can attract venture capital.
An example is the Muscular Dystrophy Association's investment in
ReveraGen, a biopharmaceutical company founded in mid 2008. From
2009 to 2013, the Muscular Dystrophy Association (MDA) committed
$1.64 million in milestone based investments to further the preclinical
investigation of a novel compound that could treat Duchenne muscular
Dystrophy, a rare dystrophy affecting roughly 24,000 boys in the US. To
date, ReveraGen has been funded exclusively by a syndicate of nonprofits
that includes, MDA, the Partnership to Eradicate Duchenne, and Cure
Duchenne. If successful, MDA expects that ReveraGen will be able to
attract commercial financing. 76,77
Accelerate Companies
The nonprofit invests in a company to speed up development related to
its mission that is likely to occur regardless, but on a much slower time
frame.
An example is Cure Duchenne's investment in Sarepta Therapeutics, a
biotech company that develops first-in-class RNA-based therapies. In
2010, Sarepta had taken Duchenne drug candidate eteplirsen through
Phase 2 trials in Europe, however the FDA placed a clinical hold on
development until a Phase 2b trial was conducted in the US. Cure
Duchenne leadership saw an opportunity to accelerate the move toward
US approval. 78 They partnered with the Foundation to Eradicate Duchenne
to invest in Sarepta with use of funds designated for a US Phase 2b trial.
Sarepta plans to submit a New Drug Application to the FDA for eteplirsen
in early 2014.79
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Cure Duchenne will potentially earn back a low multiple of its investment,
and does not hold equity in Sarepta. 80,81
Reprioritize Platform or Multipurpose Intellectual Property
The nonprofit invests in a company that is developing a multipurpose
development platform or class of therapeutics. In exchange for the
investment, the company includes the nonprofit's disease of interest as a
priority in applying its technology or intellectual property.
An example is Cystic Fibrosis Foundation's investment in Aurora
Biosciences, an early stage high-throughput drug screening company,
which kicked off of the Kalydeco success story told at the beginning of
this chapter.
Another example is Cure Duchenne's investment in Prosensa. In 2004,
nonprofit Cure Duchenne invested $1.3 million in Prosensa, an early
stage company that was hoping to use its antisense and exon skipping
technologies to treat neuromuscular diseases. Cure Duchenne funded the
company, and in exchange Prosensa made Duchenne Muscular Dystrophy
one of its priorities. Within a few years, Prosensa earned a several million
dollar venture capital investment. In 2009, pharmaceutical company
GlaxoSmithKline committed $650 million to further the development of
four of Prosensa's compounds. As a result, Drisapersen, a drug to treat
Duchenne, is finishing Phase 3 trials with breakthrough drug status, and
is expected to earn FDA approval in 2014, making it the first ever
approved treatment for Duchenne.
Cure Duchenne holds equity in Prosensa, which had an Initial Public
Offering in 2013.82 The return on investment could be significant for the
nonprofit, whose budget averages under several million per year.
Several large venture philanthropies have created investment programs that are
analogous to mini venture capital funds either within their foundation or in a
subsidiary or affiliated nonprofit. Examples include the Multiple Sclerosis
Society's Fast Forward, and the Muscular Dystrophy Association's Muscular
Dystrophy Venture Philanthropy (MVP). Nonprofits such as CHDI, who view
themselves more as virtual biotech companies, tend to seek investments and
partnerships on an ad hoc basis, as it fits their development strategy.
50
Figure 2.9 shows a sampling of venture philanthropies and the amount they
spend on company investment programs. The nonprofits included in Figure 2.9
are all among the top 30 largest venture philanthropies in terms of annual total
expense.
Figure 2.9
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The Muscular Dystrophy Association's Muscular Dystrophy Venture Philanthropy
(MVP) is an example of a programmatic investment fund. MVP invests in a
portfolio of small companies that are developing neuromuscular therapeutics.
To accomplish this, MVP employs elements of venture capital practices such as a
rolling sixteen week, iterative evaluation process that includes professional
diligence on the company from the perspectives of science, management,
finance, legal, and intellectual property. MVP invites its science and business
advisors to participate in monthly teleconferences where decisions are made
about potential investments, which typically are milestone based and up to $3
million. Not only does MVP offer attractive business terms, it bills itself as a
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$ 176 $17 M since 2009
$ 83 $10 M since 2008 ($5 M provided by GatesFoundation)
$ 68 $84 M to industry since 2002, >150 grants
$ 25 $11 M since 2007
$ 14 $1M in 2011
$ 6 >$3M since 2004
$ 6 $14 M since 2000
A
value-adding partner with scientific and regulatory expertise, and with access to
drug development and venture capital partners.83
Figure 2.10 shows MVP's portfolio since 2009. Although not shown in Figure
2.10, MPV also invests in sponsored academic projects that are seeking
commercial spin-off. It is worth noting that sponsored research is itself an
important form of investment. MVP demonstrates more transparency than most
of the nonprofits interviewed, who had confidentiality issues surrounding
disclosure of some portfolio investment details such as the amount invested.
Figure 2.10
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Despite similarities with private venture capital, nonprofit investments remain
distinctly mission based. In order to maintain nonprofit status, such
investments must meet charitable criteria defined by the Internal Revenue
Service (IRS). The IRS allows nonprofits to make risky loans and investments,
known as Program Related Investments (PRIs), only if they meet the following
criteria:
1. The primary purpose of the investment is to accomplish a charitable
mission.
2. Earning a financial return is not a significant purpose of the investment.
a. The IRS suggests a litmus test: A for profit investor would require
better terms in order to make the same investment.
3. The company being invested in cannot take part in lobbying or political
campaigns.84
All of the interviewed nonprofits indicated that they try to approach negotiating
financial returns on their investments professionally, with varying degrees of
aggressiveness, while keeping well within the bounds of PRIs. But without a lot
of precedent to go by, there is considerable variation in attitudes toward
financial returns. For example, one organization reported seeking returns in
proportion with the risk, often taking equity in early stage small companies or
up to 10x returns, while taking 3-5x multiple return if they are investing at a
later stage, such as Phase 2 trials. They view negotiating decent, though sub-
market, returns as part of their duty to their mission, since it can enable them to
reinvest in further work. Several other nonprofits interviewed report preferring
multiple returns, almost always sticking to a conservative 3-4x multiple, and
only occasionally taking equity because their legal or accounting offices view it
as more complicated and "hard to value as an asset." And still others, such as
CHDI, seek to avoid any potential conflict of interest by only making low interest
loans due at milestones successes. Despite this range, all nonprofits
interviewed emphasized that the mission is most important, and that above all
they want the biotech community to view them as a source of support.
Financial return is just one of the key terms in a biomedical venture
philanthropy investment. Figure 2.11 lists some of the other key terms that were
highlighted in interviews. As with returns, there was a range of views on the
relative importance of each term. For example, the majority of interviewed
nonprofits considered IP interruption rights to be one of the most critical terms
across all of the deals, while several nonprofits reported only rarely requesting
it.
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Figure 2.11
Some Key Terms in Biomedical Venture Philanthropy Investments
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then the nonprofit has a right to the IP for application to
the disease of interest.
Milestones The nonprofit defines clear phases of development which
the company must meet in order to continue the
partnership.
Publication The nonprofit requires certain study results be shared or
Requirements published in a timely fashion.
Publicity The nonprofit and/or company requests mention in all
press releases and publicity related to the project.
Reporting The nonprofit defines its rights to information and
requirements reporting from the company.
Structure & Multiple based return, milestone repayments, royalty
Financial Return share, equity, loans.
Source: Interviews
Inform
Nonprofits can inform stakeholders by consolidating and communicating
disease-relevant information, providing platforms and forums for sharing
information, and by communicating patient interest through advocacy.
Often nonprofit group websites are the first to pop up in Internet searches
related to a disease, and nonprofit leaders are often called upon for commentary
in media articles. Nonprofits can inform patients about their diagnosis, access
to care, treatment options, clinical trials, and advocacy opportunities. They can
inform researchers about available research tools and facilitate collaborative
information repositories. For companies, nonprofits can provide input and
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consulting on science, regulatory climate, market dynamics, research tools,
partnering opportunities, the potential benefit of applying research to other
similar diseases, and repurposing opportunities. For example, when Genzyme
was deciding to enter the Huntington's disease space, they called upon CHDI to
help educate them about resources. 85
One of the traditional roles of disease nonprofits is activism and advocacy at the
state and federal level on topics such as reimbursement, research funding, and
the approval process. Private foundations are, however, restricted from outright
lobbying, while public foundations are able to lobby within limits set by IRS
rules.
Soon after the FDA's 2004 approval of a new Multiple Sclerosis (MS) drug called
Tysabri, it was linked with several cases of a rare and fatal brain infection. In
response, drug maker Biogen-Idec voluntarily withdrew Tysabri from the market
for further evaluation. The MS Society and other patient groups were
instrumental in working with Biogen-Idec and the FDA to review safety and
efficacy information and to convey the risk appetite of MS patients.86 The MS
Society arranged for a day of testimony from patients, who voiced desire to
make their own informed choices about if and when to risk using the drug,
given its benefits to patient with highly aggressive and otherwise untreatable
MS. Ultimately, the FDA allowed Tysabri to return to the market under special
prescription and with a "black box" warning. 87 Patients with aggressive MS, in
consult with their physicians, continue to manage their own risk calculus and
benefit from the drug, while mandated postmarket surveillance and
transparency have helped to identify PML risk factors and reduce the likelihood
of the adverse event.
The Expanding and Promoting Expertise in Review of Rare Treatments Act
(EXXPERT) Act, passed by congress in 2012, was promoted by many disease
nonprofits, and helps to solidify the role of advocates in the FDA approval
process by expanding the cooperation between the FDA and outside experts,
patient groups, and care givers when considering approvals for rare diseases.
Engagement with FDA can also help establish Orphan or Breakthrough Therapy
designations, which can make pursuing clinical trials significantly more
attractive to companies that are deliberating whether to move forward with a
potential therapy.
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Shape
Nonprofits can shape the market forces that govern whether there is viable
commercial interest in a diagnostic or therapeutic area. They can work to
compensate for gaps in market incentives or remove market inefficiencies. They
can shape markets by mobilizing, pooling, guaranteeing, subsidizing, linking, or
splitting demand.
Compensating for market incentives
Because drug makers and generics manufacturers are not often
incentivized to reposition off-patent drugs, disease nonprofits often drive
such efforts. MJFF, for example, committed $3.4 million in 2010 to
funding trials to evaluate repositioning several off-patent and nearly off-
patent drugs for the treatment of Parkinsons.
If drug makers lack incentive to split demand by stratifying disease
populations, nonprofits can drive personalized medicine. For example,
the MMRF is funding a landmark 1,000 person study of multiple myeloma
patients with the goal of identifying genetic markers of disease subtype
that will allow better targeting of existing therapies, and open the door to
targeted therapies in the future. 88
Linking demand
Sometimes research on a rare disease has the potential to be applied to
other larger market diseases. For example, Sanfilippo is rare single gene
disorder that causes neurodegeneration in children. Researchers
confirmed in 2009 that Sanfilippo pathology, like Alzheimer's disease,
involves the accumulation of tau proteins in the brain. 89 Sanfilippo
nonprofits seek to inform and persuade industry that investments in
Sanfilippo therapies, with smaller and shorter clinical trials, could be a
cost effective proving ground for later applications to Alzheimer's.
Shaping market forces
The Gates Foundation and Clinton Foundation have led the way in forging
public private partnerships to shape market forces for global diseases.
The Clinton Foundation Clinton Health Access Initiative (CHAI) uses
market shaping techniques to impact HIV/AIDS care in developing
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countries. While their primary goal is to increase access, similar
techniques could be used to incentivize the development of new
diagnostics and therapies. CHAI has:
- organized a buyers cooperative of 70 developing countries for
HIV/AIDS medications.
- campaigned to support the use of generic AIDS drugs, which pressured
companies with patented drugs to cut prices in order to maintain
market share.
- built local demand in developing countries.
- provided consulting services to drug makers in order to educate them
about how to access untapped market demand in developing
countries. 90
The Gates Foundation together with the GAVI Alliance and government
partners were the first to use advance market commitments (AMCs),
which is the underwriting or guaranteeing a viable market if a new
vaccine or drug is successfully developed. The pilot pneumococcal AMC
offers a bulk purchase over ten years at a fixed price for pneumococcal
vaccines that meet a set of technical criteria determined by the World
Health Organization. The AMC contract also requires the manufacturer to
agree to a long term price cap after the period of the AMC. 91
Pharmaceutical companies Pfizer and GlaxoSmithKline have both
responded to the incentives and created sophisticated AMC-eligible
vaccines, and the program is on pace to immunize 75 million children
across 51 countries by 2015. 92
Three Case Studies
Three interesting case studies are presented in Appendix A. Together they
compare and contrast the range biomedical venture philanthropies within the
single gene disorder space and highlight different lessons. The cases also
demonstrate the application of the framework described above.
-Jonah's Just Begun: A resource-constrained "grassroots" rare disease
organization
- Duchenne Muscular Dystrophy: Multiple nonprofits competing,
complementing, and cooperating
- CHDI Foundation: A nonprofit virtual biotechnology company
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Resource Allocation
The framework presented above is intended to characterize disease focused
nonprofit resources and the core venture philanthropic functions to which those
resources can be allocated.
A next step would be developing an additional framework or guide for how
allocate their resources amongst these core functions and activities. While that
is beyond the scope of this thesis, I can offer some preliminary impressions.
At the highest level, determining an allocation strategy involves "a constant
process of surveying the disease landscape for roadblocks and obstacles, and
then either removing or routing around them." 93 Because different diseases
present different landscapes, and because nonprofits have varying resource
constraints, there is no one-size-fits-all resource allocation. To begin to
identify both the available routes and the impeding roadblocks toward new
treatments, nonprofits can ask some basic questions such as:
- Is there a basic scientific understanding of disease pathology?
-Are there promising therapeutic strategies?
-Are there promising therapeutic candidates?
-What are the impediments to translational research?
-Are there infrastructure for clinical trials?
-Are there any private companies investing in treatments? If not, why?
- Is the size, length, and cost of clinical trials deterring commercial interest?
-Are other nonprofits active in this disease space, and what functions are
they serving?
Considering where a disease is situated in the four quadrants depicted in Figure
2.12 may be useful in determining a strategic direction.
[Figure 2.12 on next page]
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Figure 2.12
Classification of Diseases
Prevalence
Multifactorial
Multiple
Myeloma
Rare/ Neglected
Progeria Huntington's
Heart
Alzheimer's disease
Common
Diabetes
Type 1
HIV/AIDS
Influenz,
Single gene/ factor
Rare & Simple (lower left quadrant)
For diseases in this quadrant, such as rare single gene disorders,
nonprofits may consider directing research along fairly well established
and relatively low risk drug discovery routes. 94 As the genetic pathway is
characterized, it points to the appropriate drug design approach such as
modifying the expression of the mutated gene; or modifying, removing or
replacing missing or malformed proteins that are produced from the
mutant gene. The main problem isn't a lack of therapeutic routes, but
rather a lack of academic and commercial interest. The nonprofit's role is
straightforward and fairly linear, pushing along development until there
is commercial interest.
For severe ultra rare diseases, clinical trials can be much smaller and
shorter (and hence cheaper) than for other diseases, and engaging with
the FDA in trial design is paramount. Pushing a therapy forward through
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Phase 3 clinical trials may be within the means of a mid-sized nonprofit,
and they may not be able to attract commercial interest until the tail end
of the process.
Starting with a budget of $300,000 in 2002, the Progeria foundation
funded the discovery of the Progeria gene. Over the next decade they
funded the creation of the first mouse model, screened for drug
candidates, and increased their budget to over $1 million annually, which
allowed them to orchestrate clinical trials through Phase 3 for the first
ever Progeria treatment.
In the language of the framework, nonprofits in this category can Direct a
pipeline from beginning to end for one or several therapeutic candidates.
And they can also Inform, by engaging with the FDA on shorter, smaller,
quicker trial designs.
Rare & Complex (upper left quadrant)
For diseases that are both rare and multifactorial, it is unlikely that a
nonprofit will be able to single-handedly deliver on its mission by
directing development, as too many bets would need to be placed on too
many therapies, each of which is likely to have only a partial, limited
impact. And more so than with a simple disease, basic research
continues to be centrally relevant.
Rather than placing all the emphasis on directing research, organizations
in this category may consider how to harness and coordinate external
interest by establishing leadership, characterizing the current state of
knowledge and activity, creating research tools, derisking the field to
attract private capital, and most importantly, forming partnerships
between academia, industry, government, clinicians and patients.
Resources are allocated across all the functions in the framework, and the
nonprofit manages a balanced toolset of venture philanthropic activities.
The Multiple Myeloma Research Foundation exemplifies this allocation
strategy. Resource constrained nonprofits in this quadrant may struggle
to have impact, but can focus on the less expensive enabling activities
such as creating patient registries.
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Common & Complex (upper right quadrant)
For a common and complex disease, there is likely to be a strongly
established market demand. The massive health care costs garner
significant government funding and academic attention. Compared to
industry and government, nonprofit budgets are likely to be relatively
small. With viable markets, the strategy of directing a portfolio of
therapies by investing in companies might be reduced to "another drop in
the bucket."
In this context, a worthwhile strategy for nonprofits might be to spur the
field in new directions, as well as to remove deterrents to commercial
activity. To spur the field in new directions, nonprofits may focus on
activities such as high risk seed grants, interdisciplinary grants for bold,
unproven "out of the box" ideas, or research on prevention. While clinical
trial networks and infrastructure are likely to exist, nonprofits may have
the opportunity to facilitate consortia to reduce clinical trials costs
through diagnostic development for surrogate clinical endpoints.
Thus nonprofits in this quadrant might allocate significantly to Enabling
activities that encourage bold and interdisciplinary ideas, study
prevention, and support clinical endpoint identification.
Common and Simple (lower right quadrant)
Prevalent, simple diseases should readily command government and
commercial attention. If adequate treatment options already exist,
nonprofits may opt to engage less in biomedical R&D, and more in work
related to patient care, access, and education. If there is a lack of good
treatment options, then the disease is likely neglected in some fashion.
Nonprofits may consider allocating their resources toward the Inform
function, to advocate for policies that address the neglect. The HIV/AIDS
movement described earlier in the chapter exemplified this role. They
may also seek to use market shaping, such as with the Gates Foundation
efforts in global health. A domestic example may be the need for new
antibiotics due to rising resistant bacterial strains, which government
policies can potentially address through augmenting incentives to
industry.
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Future research could survey allocation strategies in the four quadrants, as well
as compare the effectiveness of differing strategies within each quadrant.
Opportunities and Challenges
In this chapter, I presented a variety of anecdotal examples in which biomedical
venture philanthropy activities appear to be effective, and I referenced a handful
of nonprofit backed drugs in or near Phase 3 clinical trials whose narratives
could potentially end up resembling that of the successful Cystic Fibrosis
Foundation-backed Kalydeco. In a sense, the entire chapter was about mapping
opportunities.
At the same time, venture philanthropy has become a buzzword in the nonprofit
arena, and some nonprofits are arguably jumping on the bandwagon in
response to expectations from donors who have heard that this is the next great
thing.
Measuring, comparing, and analyzing the effectiveness of biomedical venture
philanthropies in accomplishing their mission is beyond the scope of this paper,
and would make a worthwhile and challenging topic for future study. Because
venture philanthropic activity has blossomed over the last decade and many
organizations themselves have undergone a series of changes, it may be
difficult or premature to assess the quality and impact of programs such as
biotech investment portfolios, especially given the long time frame of drug
development. 95 But several issues appear critical even at this early date:
As biomedical venture philanthropies seek to fulfill their potential, they will
need to avoid pitfalls and overcome challenges including:
-The pitfall of becoming too risk averse, too profit-driven, or too industry
dominated, as nonprofits increase their focus on investments and
potentially consider returns on investment to be important to their financial
sustainability.
- The pitfall of becoming too overbearing of a "central planner," in the case of
nonprofits that command substantial resources in their disease space.
-The challenge of navigating the sparse regulatory precedents governing
biomedical venture philanthropies with significant PRIs.
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-The challenge of maintaining patient and donor trust and nonprofit
accountability in the context of less transparency due to confidentiality
agreements.
-The challenge of addressing conflict of interest issues surrounding holding
a financial stake in specific therapies.
The task of addressing these challenges does not fall solely upon nonprofit
leaders, but depends upon donors, policy makers and the public at large
deciding upon the role that they want nonprofits to play.
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Conclusion and Future Research
Chapter 1 quantified nonprofit sector resources and found that nonprofits
command particularly significant resources within a subset of therapeutic areas.
Chapter 2 and Appendix A presented a framework and case examples for how
biomedical venture philanthropies seek to leverage their unique position and
resources toward impacting and transforming the research and development
landscape. Appendix B contains the spending data collected for the quantitative
chapter, which may be a useful reference for future research.
Topics for future research include:
Understanding the factors contributing to the allocation of nonprofit
resources across therapeutic areas.
- Quantifying and assessing the allocation of nonprofit resources toward
strategic functions.
- Developing a framework for resource allocation based upon characteristics
of the disease landscape.
-Analyzing resource allocation beyond biomedical research and development,
to include other important nonprofit functions such patient care programs.
-Assessing and comparing the effectiveness of venture philanthropic
strategies and programs.
- Investigating the potential conflict of interest problems in biomedical
venture philanthropies that hold financial stakes in particular drugs, and
proposing guidelines to address this.
Continuing to study the contribution of nonprofits to biomedical research and
development is important for several reasons. From an academic standpoint, it
is an important element in understanding the dynamics of the drug
development landscape. From a practical perspective, it can inform best
practices in the nonprofit community and warn of potential challenges. From a
greater societal perspective, it can bring lessons from nonprofit strategies into
other sectors.
The nonprofit, for profit, and public sectors have overlapping objectives and
challenges with respect to biomedical research and development, and there is a
cross pollination of strategic lessons. Just as venture philanthropies adopt
business practices, companies that experience the benefit of participation in
pre-competitive consortia may take increased initiative toward collaborative and
open research models. Many government programs face similar opportunities
and challenges as nonprofit programs. Demonstrating this point, the Israeli
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government approached the JDRF to join forces and launch Israel's first disease
specific research program, officially cobranded as a Israel-JDRF joint effort. The
NIH administers Small Business Innovation Research grants, and the Foundation
for the NIH manages a public-private Biomarkers Consortium. Likely there are
untapped opportunities for shared strategies. For example, perhaps the NIH
could expand its support for the development of translation-enabling tools such
as optimized drug discovery reagents and other tools for preclinical research.
Identifying such opportunities could lead to more systemic solutions to the gaps
and problems that nonprofits are seeking to address repeatedly in different
disease areas.
With a trend toward increasingly networked biomedical research and
development and the rise of biomedical venture philanthropic methods, the role
of the nonprofit sector is more important than ever before and lessons learned
-- both from successes and failures-- can help shift how all stakeholders in
medicine approach the development of better diagnostics and therapeutics.
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Appendix
Appendix A: Three Case Studies
Jonah's Just Begun: A resource-constrained, "grassroots," rare Disease organization3
Background
Given that the strongest resource this organization has is people, the case
narrative is more personal.
In 2010, Jill Wood and her husband received the devastating news that their two
year old son, Jonah, had a recessive single gene defect called Sanfilippo
Syndrome Type C also known as Mucopolysaccharidosis IIIC, a lysosomal
storage disease which results in the absence of an enzyme for breaking down a
polysaccharide called heparan sulfate. Though her son was asymptomatic with
the diagnosis as prompted by a mild bone deformity, the prognosis was bad.
Wood's doctor explained that Jonah, who had so far been hitting all of his
developmental milestones, would soon begin to slow down in his development,
then eventually reverse. He would suffer cumulative brain damage, eventually
loose his sight hearing, and ability to walk and talk, and he would likely die of
organ failure in his teens to mid twenties.
There was no treatment for his disease, only palliative care. Woods doctor,
however informed Wood that there were clinical studies underway for other
lysosomal storage diseases, and that although there existed scarce preclinical
research and no clinical studies in sight, a similar approach could, possibly,
work for treating Sanfalippo Type C. What Wood heard her doctor saying was
that she herself would need to push for these studies. In that moment, Wood
became an activist. She went home, read everything she could find on the
internet related to her son's disease, and founded a nonprofit called Jonah's Just
Begun.
Resources
Starting from scratch and with no other strong nonprofits in existence devoted
to Sanfilppo Type C, Wood set out to build Resources for Jonah's Just Begun (JJB).
I Unless otherwise cited, case material draws from an interview with Jill Wood, and the
Jonah's Just Begun website.
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Leadership
One of the organizations greatest assets is Wood's sheer force of will. To
meet Jill Wood is to meet a warrior. She and her husband constitute a
highly capable, versatile and passionate leadership team.
Wood also recruited Sean Ekins, a former pharma scientist, who
volunteers his time as the organization's science and industry advisor and
Project Manager. Wood met Ekins at a conference, where she compelled
him to join her crusade. Woods is exceptional at compelling people. She
communicates her efforts with clarity, thoroughness, expertise, urgency,
inspiration, humor and tremendous likability.
Networks
Wood refers to the networks that she has built as her "scientists", her
"moms" and her "mentors." She also engages with a network of other
rare disease nonprofits, including several international Sanfalippo Type C
organizations.
Wood put together her network of science advisors, initially, by cold
calling the authors of papers about other Sanfilippo subtypes (there was
virtually no research being done on Type C). Many of them had never
met someone affected by the disease before. Her scientific advisory
consists of doctors, clinical geneticists and research scientists. To build
her network of "moms," she has spent countless hours scouring and
posting on social networks and message boards, connecting with the
families of affected children. She has travelled to France, Spain, and
Portugal to meet other Sanfalippo families and organizations. Among her
hurdles in finding the patient population are language barriers, multiple
names for the disease, privacy regulations, and the fact that most
children with Sanfilippo are misdiagnosed until the disease is highly
progressed.
Knowledge
At the time of her son's diagnosis, Wood was a hairdresser with no
background in, science, drug development, or nonprofit management.
Her husband, a camera operator, was also lacking relevant educational or
professional background. Woods undertook a rapid self-education by
67
reading everything she could find about Sanfilippo and similar diseases
on the internet and in academic journal articles, attending conferences,
and talking with scientists. Within a year, it Wood and Ekins could easily
be called the world's foremost experts on the state of Sanfalippo Type C
research and development. She was also possibly the only person in the
world, at the time, seeking to a 360 degree view of the disease subtype
from a drug development vantage point.
Funds
The families affected by Sanfilippo Type C lack a fortuitous access to
wealth. Their fundraising is grassroots, one neighborhood event at a
time. Woods first fundraiser was a wine tasting event organized by her
mom and best friend. 96 In 2010, JJB's budget was $44, 515.97 In 2011
Woods supplemented donations by entering a contest for nonprofits run
by Chase Bank and winning a prize of $25,000 . Sean Ekins has also
helped the organization to apply for federal funds. JJB's 2011 budget
was $109,591. 98
Functions
Enable
Wood's primary enabling activity has been forming a patient registry with
her network of Sanfilippo families, which she hopes will be useful in
clinical studies.
Direct
Wood's top priority has been to advance preclinical research, with the
goal of derisking the field enough that she could eventually attract
commercial interest to clinical studies. With barely any funds, Woods'
only available funding strategy was to seed new research that could then
earn follow on government grants.
Wood's first activity was to fund a University of Montreal biochemist
named Alexy Pshezhetsky. Pshezhetsky's name was one of two scientists
that came up in Woods search for people interested in Sanfilippo Type C.
His team had identified the genetic mutations of Type C in 2006, along
with similar genetic work in other lysosomal storage diseases.
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Wood flew to Montreal to meet him, and as she had noted with other
researchers she had sought out, "Many of the scientists had never met
any parents of children with the diseases they studied. They needed
direction, and motivation, as much as they needed funding." 99
Wood compelled Pshezhetsky to push forward on drug development for
Sanfilippo Type C, and offered Pshezhetsky her entire grant budget of
$20,000. Pshezhetsky accepted the grant and began working on a
protocol for a mouse model. Within a year, he had applied for and been
awarded a follow on grant by the Canadian government of $600,000 over
three years to pursue his Sanfilippo Type C drug design.
Wood is currently working to raise money, along with other Sanfalippo
Type C families, to fund a Natural History Study.
With preclinical research underway, Ekins incorporated Phoenix Nest, a
virtual biotech that they hope will be able to derisk drug candidates and
attract commercial interest. Ekins has applied for a federal Small
Business Innovation Grant (SBIR).
Inform
Woods joins other rare disease organizations in advocating for the
importance of special regulatory pathways for ultra rare diseases.
Woods also partners with other families and organizations related to
mucopolysaccharidoses, to advocate for the introduction of low cost
screening in newborns, which not only would enable better care but
would also enable pre-symptomatic clinical trial cohorts.
Woods raises awareness about Sanfilippo Type C by leveraging one of the
only resources she has: her voice. With her communication skills,
inspirational story, and knock-down-the-door mentality, she succeeds in
gaining a lot of earned media. She has appeared on cnn.com and has
been profiled in major publications. Her husband, who worked on the
camera crew for CBS show, struck up a conversation with actor Johnny
Miller. Wood and her husband compelled Miller to lend his celebrity voice
to raising awareness. He appeared on CNN and talked about about
Sanfilippo Type C and rare childhood diseases, urging viewers to donate
to Jonah's Just Begun.
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Shape
Wood seeks to leverage similarities between Sanfilippo and Alzheimer's in
order to change the calculus of potential industry partners and
commercial investors. Researchers confirmed in 2009 that Sanfilippo
pathology involves the accumulation of tau proteins in the brain. 100
Alzheimer's disease also involves the aggregation of tau proteins. Wood
makes the case that investments in clinical development of Sanfilippo
therapies, with smaller and shorter clinical trials, could be a cost effective
proving ground for later applications to Alzheimer's.
Conclusion
Phase I/Il clinical trials are underway an enzyme replacement and genetic
therapy to treat Sanfilippo Type A, and will help light the way for the other
disease subtypes. But with Wood and other Sanfilippo Type C families struggling
to put together funds for a Natural History Study, their virtual biotech, Phoenix
Nest, remains barren. It is difficult to imagine how they will get to the next step
quickly, which likely would require a dramatic increase in fund raising. But then
again, it would have been difficult to imagine how Jonah's Just Begun could have
accomplished what it has in under three years. This case provides an example of
how an organization can achieve impact despite severe funding-constraints.
Wood for her part, continues to rise to the challenge. She says she isn't hopeful,
though, because she "prefers action to hope."
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Duchenne Muscular Dystrophy: Multiple nonprofits competing, complementing, and
cooperating4
Background
There are three prominent organizations, as well a host of smaller family
foundations, whose mission includes developing new treatments for Duchenne
Muscular Dystrophy (DMD). The Muscular Dystrophy Association (MDA), Cure
Duchenne, and Parent Project Muscular Dystrophy (PPMD) together display
several dynamics: they collaborate on a common goal, complement each other
with priorities, strategies and pipeline hypotheses, and compete with each other
for donor funds.
DMD is a genetic muscle disorder affecting males. With an incidence of 1 in
3,500 male births, DMD qualifies as a rare disease. The DMD single gene
mutation impairs production of a protein called dystrophin, the absence of
which leads to progressive muscle weakness and death, typically in a male's late
twenties.101
The Muscular Dystrophy Association (MDA), famed for its Jerry Lewis telethons,
is the largest and most well-known nonprofit that focuses on muscular
dystrophies. Founded in the 1950s, MDA's mission includes over 60 diseases
covering all forms of muscular dystrophies, amyotrophic lateral sclerosis (ALS),
and other neuromuscular diseases. The majority of the diseases are genetic,
though some are autoimmune. DMD is one of the top ten focuses of MDA's
basic and translational research programs. MDA focuses equally on patient
education and care services, and supports 200 care clinics nationwide.
Cure Duchenne and Parent Project Muscular Dystrophy (PPMD) are both smaller
nonprofits that focus exclusively on DMD. PPMD maintains active programs in
patient care and advocacy, while Cure Duchenne is focused exclusively on drug
development. Both organizations are still run by their founders: in both cases,
mothers whose sons were diagnosed with DMD.
Resources
'"Unless otherwise cited, material from this case draws from nonprofit websites and
interviews with Jane Larkindale and Michael Kelly.
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Leadership
MDA. Steven Derks has been CEO of MDA since 2012. Formerly CEO of
Illinois division of American Cancer Society, he brought experience in
improving patient services. Prior to joining ACS in 2002, he was vice
president at a health care services network that included 10 hospitals and
200 sites of care.
Within the organization are several scientific directors, including Jane
Larkindale, PhD, who acts as Director of Translational work, and who was
previously a biochemistry research scientist.
PPMD. Pat Furlong, president and CEO of PPMD, founded the organization
in 1994. Furlong was working as a part time nurse when doctors
diagnosed her two sons with DMD in 1984. Furlong did not accept that
there was little hope or help for them. She chose the name of the
organization to reflect its grassroots nature and its dual focuses on both
improving patient support and care and investing in research toward
better treatments. Both of Furlong's sons lost their battles with
Duchenne, however Furlong's battle on behalf of their memory and on
behalf of other affected families continues.
Cure Duchenne. Debra Miller, President & CEO of Cure Duchenne,
founded the organization in 2003 after their son was diagnosed with
Duchenne. Miller's prior professional background was in sales and
marketing.
Reporting to Miller is Chief Scientific Officer Michael Kelly, PhD. Prior to
joining Cure Duchenne in 201, Kelly was a senior pharmaceutical
executive with more than 25 years experience in drug discovery and
development.
Knowledge
All three command scientific and business expertise, and MDA and PPMD
both host research and patient care conferences.
Networks
All three organizations maintain science and industry networks and
advisory boards featuring top scientists in the field. MDA and PPMD
cultivate patient and caregiving and advocacy networks, whereas Cure
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Duchenne is less of a patient-facing organization and focuses exclusively
on drug development.
Funds
The three organizations compete for donors within the Duchenne
community. MDA's 2011 total expenses were $176 million, with $38M
going to research, and $8 million to the DMD. PPMD's 2001 expenses
were $6 million, with $4 million toward research. Cure Duchenne's 2011
total expenses, solely devoted to research, were $1million. 102
Functions
Enable
Basic Research. MDA has a long tradition of supporting academic
research, and is the biggest funder of Duchenne research. It has a
traditional grant application process that is reviewed by an advisory
board of leading clinicians and scientists. MDA-funded basic research
provides a foundation for drug development. For example, since the
1990's MDA has supported basic science toward development of the
treatment strategy called exon skipping.
Animal model. The lack of an adequate animal model for Duchenne has
severely hindered drug development efforts. In 2012 Cure Duchenne
funded the development of a better mouse model, which they hope to
use in testing antisense drugs.
C/inical trials and biomarkers. There is a well-established clinical trial
network, called the Cooperative International Neuromuscular Research
Group (CINRG). A fourth and smaller Duchenne nonprofit, the Foundation
to Eradicate Duchenne, is supporting their work in identifying
biomarkers.
Inform
MDA and PPMD are both highly active in educating patients and
caregivers, holding conferences, raising public awareness about muscular
disorders, and engaging in advocacy. For example, they were successful
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in advocating for the MD-CARE act, signed into law in 2001, which
directed the NIH and CDC to develop focused MD research and patient
care programs.
By the time Miller founded Cure Duchenne in 2003, MDA and PPMD were
already leading the way in patient education and advocacy, and Miller
opted not to invest significant resources in either patient care or
information activities.
Direct
All three nonprofits invest in and partner with private companies. They
have somewhat different objectives for their company investment
portfolios. MDA explicitly seeks to fund high risk companies and projects
that otherwise would not yet attract commercial capital. Cure Duchenne's
objectives also include trying to accelerate the work of companies and
projects that likely would be viable for private funding. PPMD
emphasizes, more so than the others, that one of their main focuses is
repurposing approved drugs in order to help the current generation of
DMD boys. Below are examples of investments made by each
organization, as well as examples of investments made by collaborative
syndicates of multiple DMD nonprofits.
MDA places a bet on an early stage company, with follow on funding from
other nonprofits. MDA led the seed funding of ReveraGen, a
biopharmaceutical company founded in mid 2008, and from 2009 to
2013, committed $1.64 million in milestone based investments to further
the preclinical investigation of a novel compound. ReveraGen has
subsequently had modest support from other nonprofits, including the
Partnership to Eradicate Duchenne and Cure Duchenne. If successful,
MDA expects that ReveraGen will be able to attract commercial financing.
Cure Duchenne accelerates Phase 2 development. Cure Duchenne
invested in Sarepta Therapeutics, a biotech company that develops first-
in-class RNA-based therapies, in order to accelerate US clinical trials. In
2010, Sarepta had taken Duchenne drug candidate eteplirsen through
Phase 2 trials in Europe, however the FDA placed a clinical hold on
development until a Phase 2b trial was conducted in the US. Cure
Duchenne leadership saw an opportunity to accelerate the move toward
US approval. Sarepta plans to submit a New Drug Application to the FDA
for eteplirsen in early 2014.
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Cure Duchenne places a bet. In 2004, Cure Duchenne invested $1.3
million in Prosensa, an early stage company that was hoping to use its
antisense and exon skipping technologies to treat neuromuscular
diseases. Cure Duchenne funded the company, and in exchange Prosensa
made Duchenne Muscular Dystrophy one of its priorities. Within a few
years, Prosensa earned a several million dollar venture capital investment.
In 2009, pharmaceutical company GlaxoSmithKline committed $650
million to further the development of four of Prosensa's compounds. As a
result, Drisapersen, a drug to treat Duchenne, is finishing Phase 3 trials
with breakthrough drug status, and is expected to earn FDA approval in
2014, making it the first ever approved treatment for Duchenne.
PPMD invests in repurposing. PPMD funded Review of Approved Drugs
Working Group (RADD), a three-way collaboration between Nationwide
Children's in Columbus, Children's National Medical Center in Washington
DC and clinical trial network TREAT-NMD. RADD's objective is to study,
test in animal models, and prioritize a list of FDA-approved drugs for
clinical testing.
A syndicate of nonprofits collaborate to fund Phase 1 trials.
CureDuchenne joined forces with several other Duchenne foundations
including the MDA, PPMD, Charley's Fund, Foundation to Eradicate
Duchenne and the Nash Avery Foundation to invest $1.5 million in
Summit Pharmaceuticals. The funds are supporting reformulation and
Phase I trial of SMT C1100, a protein replacement therapy.
A syndicate of 12 nonprofits collaborate to found a for profit company.
Twelve small DMD nonprofits came together in 2012 to collectively invest
$1.1 million in Halo Pharmaceuticals, an early stage biotech company.
Halo was founded when two families affected by DMD acquired the rights
to an experimental anti- fibris compound called halofuginone. They
purchased the compound for $500,000 from an Israeli biotech company
that had decided not to pursue further development. The syndicate of
nonprofits that subsequently funded Halo consist of: Action Duchenne,
Coalition Duchenne, Cure Duchenne, Duchenne Now, The Duchenne
Research Fund, Hope for Gus, Hope for Javier, Jain Foundation, Michael's
Cause, PPMD, Ryan's Quest, and Zubin's Wish. Tom Wicka, founder of
the Nash Avery Foundation states, "This level of unification and
engagement across the patient advocacy community for an early-stage
drug candidate is extremely rare, and we are grateful for the support and
vision of our funding partners."103
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Conclusion
With a host of drug candidates in Phase 1 and 2 trials, and a couple of
treatments entering Phase 3, the DMD community is hopeful. What is most
notable about the DMD space is that, despite being a rare single gene disorder,
there are a multiple well-resourced and active nonprofits. To some degree they
specialize in different core functions. MDA supports the bulk of basic research,
and because it addresses many similar diseases, has the resources to establish a
vast patient care program. PPMD supplements MDA's patient care program by
focusing only on DMD. All three invest in translational work and private
companies, with Cure Duchenne being solely devoted to such activities.
While some might argue that DMD nonprofits are overly fragmented, a contrary
argument seems to be proving more valid: a healthy competition amongst the
venture philanthropies protects the field from excessive "central planning."
Each of the nonprofits have different scientific and investment hypotheses, and
at times they also persuade each other to collaborate and pool investments. If
venture philanthropy is analogous to venture capital, a disease space with
multiple nonprofit investors more closely achieves the robust dynamics of the
private investment market.
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CHDI Foundation: A Virtual Nonprofit Biotechs
Background
CHDI Foundation is a mature and well-resourced nonprofit that has been
working toward a cure for Huntington's Disease (HD) for nearly a decade. It is a
private foundation funded by an anonymous high net worth individual, which
allows the organization to be fully focused on science without having to worry
about publicity or raising funds.
CHDI employs 65 people directly including over 30 staff with PhDs, and several
with MDs and MBAs. It also employs roughly 600 full-time equivalent people in
other organizations.
Robi Blumenstein, President of CHDI, describes the organization as a "nonprofit
virtual biotech." Having an outsourced model rather than maintaining their own
labs reflects the exploratory nature of CHDI's programs and affords a "leanness,
agility, and flexibility with regard to scientific strategy." It also allows them to
"reach out to the best in the world, rather having to try to recruit them."
HD is a neurodegenerative single gene disorder typified by movement and
cognitive impairment that typically begins to appear around mid life, and
progresses to death. It is caused by an expansion of the number of trinucleotide
CAG repeats in gene huntingtin, a protein that regulates protein trafficking and
neuronal life cycle.104
When CHDI was founded nearly a decade ago, Blumenstein and his cofounders
observed that there were great university scientists conducing research on
Huntington's as well as an established group of clinicians who were capable of
carrying out trials on HD. Blumenstein recalls, "What was missing was good drug
candidates." At the time, the group of clinicians was recruiting patients for a
ten year trial of a nutraceutical. Blumenstein determined that the first step in
curing Huntington's would be translational research. He hired a former
pharmaceutical manager to set up a program that would seek to validate drug
candidates, and a nonprofit virtual biotech was born.
Resources
5 Unless otherwise cited, material for this case draws from the CHDI website and
interviews with Robi Blumenstein and Simon Noble.
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Leadership
Robi Blumenstein serves as the President of CHDI with a large degree of
executive autonomy. Prior to taking on this role, he had a successful
career in merchant banking and was a partner at well known asset
management, venture capital, and private equity firms. Blumenstein
recruited several former high level managers from pharmaceutical
companies to head CHDI's science and clinical programs.
Knowledge
CHDI holds forums and workshops for the research community, and its
expert staff keeps abreast of science and industry.
Networks
CHDI approaches network building more like a private company than like
a nonprofit. Since it does not raise funds from a donor base, CHDI does
not expend a lot of effort on public relations.
Funds
CHDI's 2011 budget was $110 million, nearly twice the amount that the
NIH devoted to HD that year. As a private operating foundation that
draws funding from a single high net worth donor who has ramped up
financial support since 2004, CHDI has steady access to funds.
Functions
Enable
One of CHDI's objectives is to attract more companies to the field.
To enable HD researchers, CHDI partners with Coriell Institute for Medical
Research to provide a Community BioRepository for storing and
distributing quality-controlled research reagents and biomaterials.
CHDI requires that the research they fund at universities for the creation
of research tools such as animal models be made openly available to the
research community without the need for licensing through Technology
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Licensing Offices. They publish and make their grant contracts available
for use by other nonprofits via the Milken Institute's Faster Cures website.
To support clinical trial sponsors, CHDI is currently building a database of
clinical sites and investigators. They are also running an observational
study and will make the results available to the research community.
Perhaps most importantly, they have funded research that has improved
clinical endpoints, including diagnostics of presymptomatic disease
progression. Since HD is a slowly progressing disease with heterogenous
presentation, the absence of markers of disease progression meant that
previous clinical trials were burdened by long durations. Without better
diagnostics, studies could only be carried out on patients already
showing symptoms of the disease, but HD disease pathology begins over
10 years before patients show symptoms. By developing diagnostics for
presymptomatic disease progression using brain imaging and chemical
biomarkers, CHDI is enabling both more efficient clinical trials and the
study of preventative medicines.
Inform
CHDI only pursues information activities that directly serve its drug
development program. CHDI does not engage in advocacy or patient
education.
CHDI provides expert consulting to industry. For example, they informed
Pfizer of drug repurposing opportunities. And when Genzyme began
considering entering the HD space, CHDI educated them about research
tools.
Shape
CHDI seeks to convince partners of the usefulness of HD research by
studying and conveying the similarities between Huntington's disease and
Alzheimer's and Parkinson's. Establishing the knowledge to link these
markets could increase the incentives for companies to invest in HD.
Direct
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CHDI has pushed forward a therapeutics pipeline through very linear and
deliberate phases of development. By funding all their research through
contracts, they keep grantees focused on drug development. They have
contracted research to develop their own drug candidates, and invested
in and partnered with companies to initiate and support several other
drug candidates.
CHDI is developing its own therapeutic candidate that inhibits an enzyme
called KMO and which they hope will improve the balance of helpful and
harmful brain chemicals in HD patients. They contracted the steps of
drug screening, lead optimization, animal model characterization, and in
vivo animal testing. CHDI's lead candidate, called CHD1246, has shown
promise in primate tests.
As described above, CHDI recognized the need for more sensitive and
novel diagnostics, and has sought to address this issue from a scientific
and regulatory point of view. To that end, they funded and partnered with
a company called KineMed to develop companion biomarkers of
therapeutic response in HD. CHDI is currently validating a host of new
chemical biomarkers through its observational clinical trial.
CHDI also invested heavily in a company called Isis in order to support
their work in discovering and developing an antisense-based drug. CHDI
paid for the application of their discovery platform to HD. In 2013, seven
years after forging this collaboration, Roche Pharmaceuticals committed
$362 in a milestone based collaboration with Isis, to move toward Phase I
trials with a combination of Isis's lead candidate and Roche's technology
for delivering medicines past the brain-blood barrier. 105 With this deal in
place, CHDI will begin receiving milestone payments from Isis to
reimburse it for its investment in the company.
CHDI is also working on repurposing partnerships. CHDI approached
Pfizer with a hypothesis that a Viagra like compound could be effective
against Huntington's Disease. CHDI offered to screen Pfizers compounds
and carry out preclinical drug development, and to hand the results to
Pfizer at no cost and no obligation to them. As a result, Pfizer is planning
clinical trials for a drug called MP-10 in 2014.
Blumenstein describes his approach to structuring his partnerships with
industry as "science first." The business terms are secondary and stem
from the scientific goals. Interestingly, despite deriving funding from a
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single donor and not focusing on patient community interactions, CHDI
maintains one of the strictest conflict of interest policies of any
biomedical venture philanthropy. CHDI's policy is:
-To receive no returns beyond reimbursement plus the time value of
money from any company that it invests in.
-To only consider higher upside returns such as royalties or multiple
returns from applications of technology that they fund to diseases
other than HD (for example, if their KMO inhibitor were to prove
effective in Alzheimer's).
Blumenstein explains that royalties could increase drug prices and/or
lead to a perception of bias in their strategy and that they "never want to
end up on the other side of the table from patients." He also prefers
contracts with companies versus equity investments, because they can
better control the definition of deliverables.
Conclusion
With a host of drug candidates in Phase I or 11 trials, including those that
resulted from CHDI support, the Huntington's community is cautiously
hopeful. Blumenstein does not allow his optimism about upcoming trials
to distract him or slow him down: "I have to assume they will all fail." His
team and partners have built an organization and an enabling
infrastructure that is ready to yield high productivity. "After ten years, I
am confident the machine is in place that is going to work."
This case demonstrates a nonprofit whose model lies at the most active
end of the biomedical venture philanthropic spectrum. It shows how
much impact a single well-resourced organization--and by extensions a
single high net worth donor-- can have in a rare single gene disorder. At
the same time, it reminds us that even with a "simple" disease, the path
to successful therapies requires years of committed development.
This case also provides an example of an uncommonly strong approach
to the uncertainty surrounding conflict of interest issues, highlighting the
need for more established community wide standards.
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Appendix B: Quantitative Data
Dcomplex Venture
IDisease 1Org Type lOrgankzation Not Assets Expenses Medical R&D IModel?
Alternating Hemiplegia of
Childhood AHC)
Ataxia Telangiectasia
Brain Cancer
Multiple Sclerosis
General
Adenoid Cystic Carcinoma
Tuberculosis
Cancer
Melanoma
General
Pediactric Cancer
Lupus
COPD (Alpha-1)
ALS
ALS
Cancer, prostate cancer
alternative treatments
Alzheimers
Alzheimer's
Cancer
Brain tumor
Cancer
Dental; Oral; Craniofacial
Diabetes
Diabetes
Diabetes (Type I & Type 1I)
Diabetes (Type 1)
Diabetes (Type 2)
Epilepsy
Longevity; Aging
Heart disease
Cancer
Tabacco Cessesation
Lung disease; COPD; Asthma;
Lung Cancer
Eye disease, blindness
Melanoma, Skin disease
Syringomyelia, Chiari,
Brain/Spinal Malformation
Tinnitus
General
Spinal Muscular Atrophy
(Pediatric)
Angelman Syndrome
Angiogenesis-based therapies
General
General: Cancer
Aplastic Anemia & MDS
Arthritis
Arthritis
Arthritis
Blindness
Cancer
Brain: frontotemporal
degeneration
Glycogen Storage Disease
Asthma; Allergies
Autism
Autism
Autism
Autoimmune disease
Dystonia; Parkinson
Multiple Sclerosis
Batten Disease
Pediactric Cancer
Brain Cancer
Batten Disease
Blooms Syndrome
Brain: frontotemporal
degeneration
Lung Cancer
Psychiatric illness:
Schizophrenia, Depression
Brain/neurological disorders
Pediatric Brain Tumors
Cancer
Alzheimers, Macular
Degeneration, Glaucoma,
Aging
General, Genomics, Stem Cell
Research
IBD
Alternating Hemiplegia of Childhood Foundation
A-T Children's Project
ABC2
Accelerated Cure Project for Multiple Sclerosis
Private Adelson
Private Adenoid Cystic Carcinoma Research Foundation
Aeras Global TB Vaccine Foundation
AID for Cancer Research
Aim at Melanoma
Private
Operating Albert and Mary Lasker Foundation
Alex's Lemonade Stand Foundation
Alliance For Lupus Research
Alpha-1
ALS Association (ALSA)
ALS Hope Foundation
Alternative Cancer Research Fund/ Prostate Cancer
Fund
Alzheimer's Drug Discovery Foundation
Alzheimers Association
American Association for Cancer Research
American Brain Tumor Association
American Cancer Society
American Dental Association
American Diabetes Associatalon (TOTAL)
American Diabetes Association (General)
American Diabetes Association (Type 1 & 2)
American Diabetes Association (Type 1)
American Diabetes Association (Type 2)
American Epilepsy Society
American Federation for Aging Research
American Heart Association
American Insitute for Cancer Research
American Legacy Foundation
American Lung Association
American Optometric Fund
American Skin Association -
American Syringomyella & Chiari Alliance Project, Inc.
American Tinnitus Association $
Private Amon G. Carter Foundaiton
Andrew's Buddies Corporation/ Fight SMA
Angelman Syndrome Foundation
Angiogenesis Foundation
Private Anna Fuller Fund
Private Anna Maria and Stephen Kellen Foundation
Aplastic Anemia and MDS Foundation
Arthiritis National Research Foundation
Arthritis Foundation
Arthritis National Research Foundation
Arvo Foundation for Eye Research
ASCO Conquer Cancer Foundation
Association for Frontotemporal Degeneration
Association for Glycogen Storage Disease
Asthma and Allergy Research Foundation
Autism Consortium
Autism Science Foundation
Autism Speaks
Autoimmune Related Diseases Association
Bachmann-Strauss Dystonia and Parkinson
Foundation
Band Against MS
Batten Disease Support and Research Foundation
Bear Neccessities Pediatric Cancer Foundation
Private Ben and Catherine Ivy Foundation
Beyond Batten Disease Foundation
Bloom's Syndrome Foundation
Bluefield Project to Cure Frontotemporal
Degeneration
Bonnie J. Addario Lung Cancer Foundation/ ALCMI
Brain & Behavior Research Foundation
Brain Research Foundation
Brain Tumor Foundation for Children
Brian Piccolo Cancer Research Fund
BrightFocus Foundation (American Health Assistance
Foundation)
Private Broad Foundation (General)
Private Broad Foundation (181 Program)
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453,000
(52,122)
1,572,000
1,160,000
475,000
935,000
38,210,000
200,000
460,000
58,700,000
11,414,000
3,609,000
14,606,000
13,888,000
75,000
107,000
3,119,000
68,620,000
45,884,000
2,642,000
1,374,385,000
22,803,000
84,623,000
$
$ 25,563,000 $
$ 652,988,000 $
$
$
$ 4,137,000 $
$ 577,000 $
$
514,000 $
$S
$ 663,000
$ 1,223,000
$ 124,000
$ 8,111,000
$ 491,082,000
$ 2,566,000
$ 7,220,000
$ 34,685,000
$ 7,220,000
$ 2,169,000
$ 26,434,000
$ 1,127,000
$ 128,000
$ 3,623,000
$ 1,171,000
$ 276,000
$ 11,234,000
$ 770,000
$ 3,335,000
$ 166,000
$ 1,108,000
$ 319,000
$ 209,400,000
$ (683,000)
$ 195,000
$ 2,793,000
$ 604,000
$ 2,076,000
$ 14,165,000
$ 27,000
229,000 $
843,000 $
1,979,000 $
2,577,000 $
4,053,000 $
1,518,000 $
47,796,000 $
320,000 $
750,000 $
2,625,000 $
7,960,000 $
10,624,000 $
9,300,000 $
13,742,000 $
296,000 $
1,230,000 $
5,762,000 $
96,483,000 $
51,696,000 $
4,617,000 $
964,970,000 $
7,795,000 $
199,999,000 $
$
3,932,000 $
9,914,000 $
616,339,000 $
24,938,000 $
66,850,000 $
63,289,000 $
470,000 $
2,064,000 $
340,000 $
1,113,000 $
31,088,000 $
818,000 $
1,657,000 $
1,825,000 $
549,000 $
23,451,000 $
2,669,000 $
1,318,000 $
55,416,000 $
1,318,000 $
673,000 $
24,692,000 $
960,000 $
47,000 $
3,365,000 $
2,072,000 $
448,000 $
56,711,000 $
716,000 $
2,045,000 $
382,000 $
831,000 $
1,346,000 $
10,000,000 $
1,044,000 $
477,000 $
297,000 $
1,300,000 $
6,500,000 $
1,732,000 $
718,000 $
184,000 $
150,000
277,000
1,403,000 Y
1,900,000 Y
3,030,000
1,300,000
39,504,000 Y
259,000
200,000 Y
1,100,000
5,500,000
7,000,000
3,085,000 Y
2,981,000 Y
164,000
1,129,000
5,522,000 Y
24,950,000 Y
16,161,000
2,440,000
148,468,000
2,500,000
44,218,000
8,844,000
13,265,000
6,633,000
15,476,000
545,000
8,623,000
120,718,000
1,700,000
2,800,000
6,930,000 Y
399,000
1,256,000
18,000
400,000
1,200,000
542,000
860,000 Y
500,000
494,000
3,173,650
266,000
975,000
10,609,000
1,085,000
315,000
9,000,000 Y
400,000
20,000
664,000
1,380,000
274,000
24,054,000
184,000
1,433,000
101,000
600,000
240,000
9,000,000
556,000 Y
470,000
50,000 Y
1,000,000 Y
12,044,000
1,000,000
25,000
180,000
$ 25,700,000 $ 40,402,000 $ 7,707,000
$ 83,833,000
$ 4,000,000
General
Spinal Injury, Paralysis
General
Urological Cancer
Canavan Disease
Canavan Disease
Cancer
Cancer
Cancer
Cancer, Leukemia
Bile Duct Cancer
Carcinoid and Pancreatic
Neuroendocrine Cancer
Cardiovascular
Heat disease, Cardiovascular
Cancer
Carcinoid and Pancreatic
Neuroendocrine Cancer
Hurler's Syndrome,
MUCOPOLYSACCHARIDOSIS
("MPS")
Ovarian Cancer
Cerebral Palsy
Chronic Fatigue Syndrome
Charcot-Marie-Tooth disease
(CMT)
Duchenne Muscular
Dystrophy
Huntington's
Lung Cancer
Chest/Spinal Deformity
Osteogenesis Imperfecta
Pediatric Cancer
Gaucher
Leukemia (Pediatric)
Neurofibromatosis
Bile Duct Cancer
Chordoma Cancer
Spinal Injury
Chromosome 18 defects
Chronic Fatigue Syndrome
Epilepsy
General
Cancer
General
Pediatric Cancer
Private Broad Foundation (TOTAL)
Bryon Riesch Paralysis Foundaiton
Private Burroughs Wellcome Fund
Butch Waits & Donald Skinner Urological Cancer
Research
Canavan Research Illinois
Canavan Research Foundation
Cancer Research & Biostatistics
Cancer Research Foundation
Cancer Research Institute
Cancer Research Treatment Fund
Can Uv - The Hepatobiliary Cancers Foundation
Carcinoid Cancer Foundation
Cardiovascular Medical Research and Education Fund,
Private Inc.
Cardiovascular Research Foundation
Care for the Cure
Caring for Carcinoid
Catrina Marcus Foundation
Celma Mastry Ovarian Cancer Foundation
Cerebral Palsy International Research Foundation
CFIDS Association
Charcot-Marie-Tooth Association
Charleys Fund
Private CHDI Foundation
CHEST Foundation/ One Breath
Chest Wall and Spine Deformity Research
Children's Brittle Bone Foundation
Children's Cancer Foundation
Children's Gaucher Research Fund
Children's Leukemia Research Association
Children's Tumor Foundation
Cholangiocarcinoma Foundation
Chordoma Foundation
Christopher Reeve Foundation
Chromosome 18 Registry and Research Society
Private Chronic Fatigue Intitiative
Citizens United for Research in Epilepsy (CURE)
Clayton Foundation for Research
Supporting
foundation
for
community Commonwealth Foundation for Cancer Research
foundation Foundation
Communities Foundatin of Texas
Cookies for KidsCancer
1,926,000,000
255,000
669,855,000
9,824,000
37,000
52,000
4,554,000
6,235,000
25,857,000
10,227,000
115,000
141,000
18,614,000
2,932,000
193,000
$
$
$
$
$
$
S
$
$
$
$
170,452,000
218,000
38,000,000
438,000
127,000
17,000
10,513,000
538,000
16,189,000
871,000
68,000
260,000
4,122,000
42,248,000
312,000
87,833,000
168,000
30,000,000
434,000
100,000
15,000
7,678,000
373,000
13,900,000
600,000
50,000
50,000
4,095,000
9,900,000 Y
170,000
371,000 $ 1,667,000 $ 1,400,000
$
$
$S
$S
$
380,000
115,000
4,046,000
1,080,000
2,274,000
40,945,000
6,989,000
373,000
465,000
1,238,000
824,000
1,994,000
6,229,000
149,000
584,000
6,265,000
361,000
32,000
7,306,000
64,936,000
$
$
$S
$S
91,000
128,000
1,394,000
1,120,000
77,000
95,000
778,000
760,000 Y
$ 1,212,000 $ 100,000
1,810,000
108,395,000
1,601,000
623,000
359,000
1,527,000
145,000
1,556,000
8,149,000
58,000
606,000
16,331,000
316,000
2,116,000
2,730,000
7,607,000
533,000 Y
93,106,000 Y
500,000
500,000
191,000
1,100,000
143,000
259,000
4,691,000
50,000
394,000
7,726,000 Y
183,000
1,394,000 Y
2,000,000
6,570,000
23,610,000 $ 5,832,000 $ 5,705,000
$ 79,000,000 $ 5,000,000
1,224,000 $ 810,000 $ 730,000
Thalassemia/ Cooley's Anemia
COPD
Spinal Injury, Paralysis
Crohn's and Colitis (IBD)
Alzheimers
Breast Cancer
Pediatric Cancer
Duchenne Muscular
Dystrophy
Juvenile Myositis (JM)
Cystic Fibrosis
Cystic Fibrosis
Cystinosis
Cystinosis
Cancer
Brain disease, immunology
Niemann-Pick
Leukemia, Cancer
Dermatology
Desmoid Tumor (Cancer)
Diabetes (Type 1)
Diabetes (Type 1)
Blindness, Macular
degeneration, retinal disease
Heart disease
General
Down Syndrome
General
Breast cancer
General
Dysautonomia
Dystonia
Dystrophic Epidermolysis
Bullosa
Cancer
Hearing Loss, Disorders,
Balance
Early Diagnosis
Aging; Alzheimer's; Macular
Degeneration
Cooley's Anemia Foundation
COPD Foundation
Private Craig H. Neilsen Foundation
Crohn's & Colitis Foundation of America, Inc.
Private
Cure Alzheimer's Fund
Cure Breast Cancer Foundation
Cure Childhood Cancer
Cure Duchenne
Cure JM Foundation
Cystic Fibrosis Foundation (CFF)
Cystic Fibrosis Resarch Foundation
Cystinosis Research Foundation/ Natalie's Wish
Cystinosis Research Network
Damon Runyon Cancer Research Foundation
Dana Foundation
Dana's Angels Research Trust
Danny Thompson Memorial Leukemia Foundation
Dermatology Foundation
Desmoid Tumor Research Foundation
Diabetes Research and Wellness Foundation
Diabetes Research Insitute Foundation
Discovery Eye Foundation
Private Donald W. Reynolds Foundation
Private Doris Duke Charitable Foundation
Down Syndrome Research and Treatment Foundation
Private Dr. Ralph and Marian Falk Medical Research Trust
Dr. Susan Love Research Foundation
Private Druckenmiller Foundation
Dysautonomia Foundation
Dystonia Medical Research Foundation
Dystrophic Epidermolysis Bullosa Research
Association of America/ International
Eagles Fifth District Cancer Telethon
Ear Research Foundation $
Early Diagnosis Research and Treatment Foundation $
Private Edward N. and Bella L Thome Memorial Foundation $
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1,610,000
4,155,000
411,175,000
6,213,000
4,550,000
60,000
539,000
1,995,000
432,000
175,449,000
443,000
1,504,000
354,000
89,272,000
210,520,000
268,000
152,000
28,529,000
293,000
1,773,000
24,851,000
1,630,000
4,000,000
7,707,000
53,241,000
3,123,000
522,000
2,684,000
1,091,000
760,000
313,763,000
772,000
1,943,000
411,000
13,537,000
16,238,000
124,000
832,000
5,558,000
216,000
12,048,000
7,982,000
406,000
1,200,000 Y
6,998,000
16,240,000
2,053,000 Y
500,000
1,518,000
973,000 Y
580,000 Y
55,000,000 Y
200,000
1,500,000 Y
269,000
11,265,000
6,596,000
121,000
650,000
3,872,000
150,000
8,000,000
7,366,000
$ 7,400,000 $ 1,338,000 $ 591,000
$ 121,492,000 $ 10,000,000
$ 79,873,000 $ 10,000,000
70,000
120,653,000
4,713,000
805,431,000
4,116,000
2,630,000
911,000
63,000
1,991,000
6,505,000
2,068,000
53,501,000
1,616,000
2,999,000
696,000
782,000
1,225,000
5,587,000
1,000,000
27,000,000
752,000
1,351,000
500,000 Y
690,000
2,618,000 $ 755,000 $ 150,000
2,475,000 $ 515,000 $ 396,000
91,169,000 $ 9,745,000 $ 1,500,000
$
$
$
$
$
$
$
$
$
$
$
$
Myelodysplastic Syndromes,
Acute Myeloid Leukemia
AIDS
Cancer
Longevity, Aging/age related
disease
Endometriosis
Epilepsy
Epilepsy
Geriatric Medicine
Menta Health
General/TAIL ESTIMATE
Congenital eye defects,
pediatric blindness
Dysautonomia
Fibrolamellar Cancer
Blindness, Retinal Pigmentosa
Private
Private
Edward P. Evans Foundation
Elizabeth Glaser Pediatric AIDS Foundation
Ellen Marks Cancer Foundation
Private Ellison Medical Foundation
Endometriosis Association
Epilepsy Foundation
Epilepsy Therapy Project
Private Erickson Foundation
Private Essel Foundation
ESTIMATE OF TAIL
Eye Birth Defects Research Foundation
Familial Dysautonomia Now Foundation
Fibrolamellar Cancer Foundation
Fight for Sight
$ 144,429,000 $
435,000 $ 1,352,000 $
16,838,000
423,000
13,111,000
519,000
81,000,000
62,660,000
750,000,000
29,000
299,000
527,000
3,132,000
$
$
$
$
$
$
$
40,907,000
508,000
13,987,000
2,160,000
8,000,000
3,930,000
$
$
$
$
$S
$
$S
194,000 $
150,000 $
639,000 $
738,000 $
Tabacco use, smoke exposure,
lung cancer, lung disease
Breast Cancer
Ultrasound
Blindness, Macular
Degenration, Retinal
Pigmentosa
AIDS
Gastroenterology
ichthyosis, skin disease
Diagnostics
Peripheral Neuropathy
Prader-Willi
Cancer, cell biology
Sarcoidosis
General
Psychiatric illness
Duchenne Muscular
Dystrophy
General
Friedreich's Ataxia
Facioscapulohumeral
muscular dystrophy
Cancer
Diarrhea
Flu / Pneumonia
General: Infectious, Misc,
Discovery/Vaccines
AIDS
Malaria
Tuberculosis
Gastrointenstinal Stromal
Tumor
Glaucoma, Blindness
General
Tuberculosis & AIDS
Cancer
Pediatric Scoliosis, Spinal
disorder
Neuromyelitis optica (NMO)
Spinal Muscular Atrophy
(Pediatric)
Giant Axonal Neuropathy
General
Hearing Loss
Rheumatic diseases
Cardiovascular
Crohn's and Colitis (IBD)
General
Diabetes (Type 1)
Hemophelia
Hemophelia; Von Wilebrand
Hepatitis B
Ovarian Cancer
Huntington's
Charcot-Marie-Tooth disease
(CMT)
Eye disease; Blindess
Sickle Cell
General
Blindness
Private Flight Attendant Medical Research Institute
Florida Breast Cancer
Focused Ultrasound Foundation
Foundation Fighting Blindness
Foundation for AIDS Research
Foundation for Digestive Health & Nutrition/
American Gastroenterology Association
Foundation for ichthyosis and Related Skin Types
Foundation for Innovative New Diagnostics (FIND)
Private Foundation for Peripheral Neuropathy
Foundation for Prader-Willi Research
Private Foundation for Research in Cell Biology and Cancer
Private Foundation for Sarcoidosis Research
Private Foundation for the NIH
Foundation of Hope for Research and Treatment of
Mental Illness
Private
Private
Private
Private
Private
Private
Private
Private
Foundation to Eradicate Duchenne
Fraternal Order of Eagles Foundation
Friedreich's Ataxia Research Alliance
FSH Society
Fund for Cancer Research
Gates Foundation (Diarrhea)
Gates Foundation (Flu/ Pneumonia)
Gates Foundation (General:
Misc./Polio/Discovery/Vaccines/Neonatal)
Gates Foundation (HIV/AIDS)
Gates Foundation (Malaria)
Gates Foundation (TOTAL)
Gates Foundation (Tuberculosis)
GIST Cancer Research Fund
Glaucoma Research Foundation
Private Glenn Foundation for Medical Research
Global Alliance for TB Drug Development
Golfers Against Cancer
Private
Private
Private
Private
Private
Private
Private
Cancer
Cancer: rare cancers
Private
Cancer, obesity Operating
Hypersensitivity pneumonitis Private
Cancer Private
Hydrocephalus
IBD (Pediatric)
AIDS
Essential Tremor
Growing Spine Foundation
Guthy-Jackson Charitable Foundation
Gwendolyn Strong Foundation
Hannah's Hope for Giant Axonal Neuropathy
Harold and Leila Mathers Charitabe Foundation
Hearing Health Foundation
Helen Hay Whitney Foundation
Helmsley Charitable Trust (Cardiovascular Program)
Helmsley Charitable Trust (Chrohn's & IBD Program)
Helmsley Charitable Trust (TOTAL)
HeImsley Charitable Trust (Type 1 Diabetes Program)
Hemophelia Association of New York
Hemophella of Georgia
Hepatitis B Foundation
HERA Women's Cancer Foundation
Hereditary Disease Foundation
Hereditary Neuropathy Foundation
Hermann Eye Fund
Hina Patel Foundation
Hitchcock Foundation
Hope for Vision
Hope Foundation
Hope Funds for Cancer Research
Hopelab Foundation
HP Therapeutics Foundation
Hsieh Family Foundation
Hydrochephalus Association
Improve Care Now
International AIDS Vaccine Initiative
International Essential Tumor Foundation
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$ 34,693,000 $
$ 31,440,000 $
$
$ 1,628,000 $
$ 2,470,000 $
$ 444,000 $
$ 436,000 $
$ 4,412,000 $
$ 861,000 $
$ 73,000,000 $
$ 3,039,000 $
$
$
$
28,449,000
26,291,000
14,397,000
512,000
25,687,000
879,000
489,000
213,000
474,000
56,000,000
359,000
16,458,000 Y
7,536,000
1,200,000
150,000
20,000,000
294,000
308,000
200,000
101,000
50,000,000 Y
300,000
281,000 $ 693,000 $ 500,000 Y
5,013,000 $ 8,838,000 $ 8,760,000
2,600,000 $ 3,044,000 $ 2,500,000
$ 1,524,000 S 884,000 $
$ 615,000 $ 213,000 $
$ 28,835,740,000 $ 3,278,792,000 $
$S
$S
$S
$S
$S
$S
195,000
4,977,000
211,000,000
40,595,000
143,000
783,000
4,043,000
7,033,000
36,739,000
974,000
$S
$S
$S
$
$S
530,000 Y
180,000
33,914,000 Y
34,048,794 Y
236,626,000 Y
261,016,599 Y
69,105,402 Y
674,844,000 Y
30,755,962 Y
725,000
2,788,000
7,007,000
29,376,000 Y
974,000
$ 528,000 $ 264,000 $ 46,000
$ 5,000 $ 4,932,000 $ 4,897,000
242,000
1,414,000
86,567,000
3,515,000
48,343,000
3,947,443,000
2,767,000
17,799,000
415,000
8,840,000
164,000
16,543,000
113,000
21,611,000
1,673,000
14,775,000
576,000
3,500,000
4,250,000
1,000,000
1,500,000
130,000
70,907,000
171,000
688,000
16,666,000
2,014,000
3,347,000
221,894,000
1,468,000
8,983,000
946,000
431,000
2,093,000
515,000
5,064,000
18,000
7,700,000
743,000
8,527,000
350,000
5,310,000
6,800,000
12,000,000
2,000,000
512,000
83,316,000
592,000
113,000
639,000 Y
13,383,000
1,408,000
3,000,000
21,167,000
23,940,000
74,050,000
28,943,000
737,000
5,000,000
79,000
200,000
1,790,000
300,000 Y
748,000
10,000
7,000,000
608,000
7,100,000
288,000
5,000,000 Y
6,800,000
10,000,000
1,000,000
287,000
59,902,000 Y
60,000
5,000,000
3,000,000
1,330,000
38,965,000
200,000
3,997,000 Y
530,000 Y
4,000,000
3,025,000
200,000,000
100,000
117,000
610,000
300,000
113,320,000 $ 25,576,000 $ 23,479,000
756,000 $ 1,532,000 $ 600,000
7,000,000 $ 5,700,000 $ 3,000,000
$
$
$
$
$
Genomics; Cancer and
complex disease
Psychiatric illness
AIDS Microbicide
Blindness, Macular
Degeneration, Retinal Disease
Rett Syndrome
Interstitial Cystitis
Interstitial Cystisis
Canavan Disease
Brain cancer, brain disease
Immune Diseases
Cystinosis
Duchenne Muscular
Dystrophy
Alzheimer's
Sanfilippo Syndrome
Congenital Mytobufar
Myopathy MTM)
Orthopedics
Psychiatric illness: Juvenil
Bipolar
Diabetes (Type 1)
General
Kidney Cancer
Diabetes, vascular disease
Cancer
General
Blindness, Macular
degeneration
Breast Cancer
Longevity, Aging
LAM (
lymphangioleiomyomatosis)
Cancer
General
Brain, Psychiatry, General
ALS
Leukemia & Lymphoma
Leukemia &Lymphoma,
Myelodyplastic Syndromes
Gastrointenstinal Stromal
Tumor
Blindness, eye disease
Limb Preservation,
Injury/Tumors
Lowe Syndrome
Cancer
Lung Cancer
Lung Cancer
Lupus
Lupus
Lupus
Lyme Disease
Leukemia & Lymphoma
Leukemia & Lymphoma
Ovarian Cancer
Blindness, Macular
Degeneration, Retinal Disease
Cancer
Pediactric Cancer
Pancreatic Cancer
Birth defects
General, Neuroscience,
Neurology
Ovarian Cancer
Brain disease
Melanoma
Mesothelioma
Mesothelioma
Pediatric Obesity and Health
Parkinson
Heart disease
General
Migraine Headaches
Multiple Myeloma
Myeloproliferative Neoplasms
Multiple Sclerosis
MucolIpIdosIs Type4
Psychiatric illness
ALS
Becker and Duchenne
Muscular Dystrophy
Charlotte Tooth (CMT)
Muscular Dystrophy
(Friedrichs Ataxia)
Muscular Dystrophy
Myasthenia Gravis
Muscular Dystrophy
(Myotubular/Myotonic
Myopathy)
Muscular Dystrophy
Private
International Genomics Consortium
International Mental Health Research Organization
International Partnership for Microbicides
International Retinal Research Foundation
International Rett Syndrome Foundation
Interstitial Cystisis Association
Interstitial Cystitis
Jacob's Cure
James McDonell Foundation
Jeffrey Modell Foundation
Jenna & Patrick's Foundation of Hope
Jett Foundation
John Douglas French Alzheimer's Foundation
Jonah's Just Begun
Joshua Frase Foundation for Myopathy Research
JSRI Foundation
Juvenile Bipolar Resarch Foundation
Juvenile Diabetes Research Foundation (JDRF)
Kelsey Research Foundation
Kidney Cancer Association
Kilo Diabetes and Vascular Research Foundation
Private Kittredge Foundation
Private Kleberg Foundation
Knights Templar Eye Foundation
Komen
Kronos Longevity Research Institute
LAM Treatment Alliance
Private
Private
4,451,000 $ 9,306,000 $ 9,000,000 Y
419,000 $ 2,349,000 $ 2,000,000
21,098,000 $ 37,733,000 $ 22,226,000 Y
30,288,000
2,871,000
991,000
439,000
474,744,000
42,820,000
169,000
$
$
$
$
$
$
$
$
1,653,000
4,958,000
884,000
1,104,000
1,418,000
30,416,000
8,000,000
362,000
$
$
1,366,000
2,500,000
85,000
70,000
809,000 Y
25,000,000
4,000,000
341,000
$ 52,000 $ 344,000 $ 100,000
S 10,710,000 $ 864,000 $ 617,000
$ 42,000 $ 82,000 $ 60,000 Y
$ 75,000 $ 77,000 $ 20,000
$ 190,000 $ 704,000 $ 567,000
527,000
48,031,000
3,850,000
11,189,000
4,276,000
3,300,000
198,880,000
$
$
$
$
$
$
$
348,000
203,785,000
2,250,000
1,729,000
650,000
756,000
10,045,000
$
$
$
$
$
$
$
80,000,000 $ 5,000,000 $
193,219,000 $ 408,978,000 $
1,536,000 $ 4,076,000 $
$
$
$
$S
$
Lance Armstrong Foundation
Larry H. Hillblom Foundation
Leon Levy Foundation
Les Turner ALS Foundation
Leukemia & Lymphoma Society
Leukemia Research Foundation
Life Raft Group
Lifelong Vision / Midwest Cornea Research
Foundation
Limb Preservation Foundation
Lowe Syndrome Associaiton
Ludwig Institute of Cancer Research
Lung Cancer Research Foundation
LUNGevity Foundation
Lupus Foundation of America
Lupus Foundation of Minnesota
Lupus Research Institute
Lyme Disease Research Foundation
Lymphoma Foundation
Lymphoma Research Foundation
Lynn Cohen Foundation for Ovarian Cancer Research
Macula Vision Research Foundation
Main Cancer Foundation
Make Some Noise Cure Kids Cancer Foundation
Marc Lustgarten Pancreatic Cancer Foundation
March of Dimes
Private Marcus Foundation
Marsha Rivkin Center For Ovarian Cancer Research
Private Mcknight Endowment Fund for Neurosciences
Melanoma Research Alliance Foundation
Mesothelioma Applied Research Foundation
Mesothelioma Research Foundation
Private Michael and Susan Dell Foundation
Michael J. Fox Foundation (MJFF)
Michael Wolk Heart Foundation
Midwest Biomedical Research Foundation (VA)
Migraine Research Foundation
MMRF
MPN Research Foundation
MS Society/Fast Forward
Mucolipodosis TypelV (ML4) Foundation
Multidisciplinary Association for Psychedelic Studies
Muscular Dystrophy Association (ALS)
Muscular Dystrophy Association (Becker/Duchenne)
Muscular Dystrophy Association (CMT)
Muscular Dystrophy Association (Friedrichs Ataxia)
Muscular Dystrophy Association (Myasthenia Gravis
MG)
Muscular Dystrophy Association
(Myotubular/Myotonic Myopathy)
Muscular Dystrophy Association (Other/General)
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16,976,000
116,000,000
430,334,000
931,000
123,405,000
$ 1,299,00034,993,000
6,000,000
41,318,000
2,108,000
299,075,000
$
$S
$
$
$
$
384,000 $ 1,972,000 $
287,000
128,264,000 Y
1,000,000
667,000
132,000
250,000
5,540,000
1,980,000
75,302,000
3,764,000
535,000
3,000,000
6,000,000
10,000,000
1,700,000
71,985,000 Y
872,000
$ 58,106,000 $ 2,835,000 $ 2,126,000
$ 796,000 $ 698,000 $ 695,000
$
$
$
397,000
190,000
4,401,000
262,000
3,310,000
(623,000)
570,000
1,439,000
7,647,000
53,000
(845,000)
2,828,000
20,000
23,177,000
54,000,000
21,370,000
11,000
30,982,000
1,800,000
21,000
21,122,000
1,153,000
3,657,000
37,000
14,557,000
1,021,000
90,123,000
196,000
1,139,000
$
$
$
280,000
36,000
113,059,000
1,200,000
4,413,000
10,232,000
1,730,000
4,524,000
298,000
730,000
10,952,000
694,000
2,688,000
1,663,000
264,000
8,143,000
206,093,000
40,430,000
1,813,000
3,689,000
6,656,000
1,400,000
286,000
103,000,000
67,917,000
216,000
2,165,000
720,000
25,186,000
1,375,000
213,777,000
29,000
1,385,000
$
$
$
$
$S
60,000
25,000
99,565,000 Y
1,000,000
2,593,000
1,115,000
184,000
3,300,000
150,000
369,000
5,700,000
479,000
1,700,000
830,000
228,000
7,263,000
30,835,000
3,600,000
1,269,000
1,200,000
5,104,000
900,000
285,000
10,000,000
62,016,416 Y
180,000
1,836,000
353,000
16,517,000 Y
1,000,000
40,257,000 Y
24,000
250,000
8,193,971 Y
$ 7,519,137 Y
$ 1,086,017 Y
$
$
613,932 y
1,333,149 Y
$ 1,568,626 Y
$ 17,701,000
$
$
$
$
Muscular Dystropjy
Myasthenia Gravis
Multiple Sclerosis,
Neurological Disease
Multiple Sclerosis,
Neurological Disease
Myotonic Dystrophy
Marfan Syndrome
General, Chronic Disease
Ataxia
Brain tumor
Pediatric Cancer
Cancer
Fertility
Gaucher
Hemophelia
Niemann-Pick
Hearing Loss
Pancreatic Disease
Parkinson
Psoriasis
Tay Sachs, Canavan
Vulvodynia
Nephrotic Syndrome
Neurofibromatosis
Stem cell
Nontuberculosis myobacteria
(NTM), lung disease
Cancer
Diarrhea, Malaria
Orthopedics
Orthopedics
Osteogenesis Imperfecta
Ovarian Cancer
Oxalosis, Hyperoxaluria
Pachyonychia
Pancreatic Cancer
Parlysis; Spinal injury
Spinal injury
Duchenne Muscular
Dystrophy
Parkinson
Malaria; Polio ;HIV; Neotatal;
Flu; TB
Pneumonia; Flu; Diarhea;
Polio
General
Pediatric Brain Tumors
Pediactric Cancer
Pediatric Endocrine Disorders
Epilepsy (Pediatric)
IBD (Pediatric)
General: Preventative; Cancer
Cancer
Phelan-McDermid Syndrome,
and (Autism)
Polycystic Kidney
Plastic Surgery
Pseudomyxoma Peritonei
(PMP)
Preeclampsia
Cancer
Progeria
Propionic Acidemia
Prostate Cancer
Pulminary Fibrosis
Pulminary Hypertension
Down Syndrome
Blindness, Macular
Degenration
Blindness, Macular
degeneralton, retinal disease
Retinobalstoma (Pediatric
Cancer,Blindness)
Ret Syndrome
Cancer
Diabetes (Typel)
General; Cancer; Diabetes
Type 1
General
Mental Health; Addiciton
Nutrition; Obesity
General: Mental Health;
Nutrition
Rheumatic diseases
General
Diabetes
Muscular Dystrophy Association (Spinal Muscular
Atrophy)
Muscular Dystrophy Association (TOTAL)
Myasthenia Gravis Foundaiton of America
Myelin Project/Brain Repair Project
Myelin Repair Foundation
Myotonic Dystrophy Foundation
Naltonal Marfan Foundation
Private Nancy Taylor Foundation for Chronic Disease
National Ataxia Foundation
National Brain Tumor Society
National Childhood Cancer Foundation (aka Cure
Search)
National Foundation for Cancer Research
National Foundation for Fertility Research
National Gaucher Foundation
National Hemophelia Foundation
National Niemann Pick Disease Foundation
National Organization for Hearing Research
Foundation
National Pancreas Foundation
National Parkinson Foundation Inc
National Psoriasis Foundation
National Tay Sachs and Allied Diseases Association
National Vulvodynia Association
NephCure Foundation
Neurofibromatosis Northeast
New York Stem Cell Foundation
NTM Info & Research
Ocala Royal Dames for Cancer Research
One World Health
Orthopaedlic Research and Education Foundation
Orthopaedic Scientific Research Foundation
Osteogenesis imperfecta Foundation
Ovarian Cancer Research Fund
Oxalosis and Hyperoxaluria Foundation
Pachyonychia Congenita Foundation
Pancreatic Cancer Action Netowrk
Paralyzed Veterans of America
Paralyzed Veterans Research Foundation
Parent Project Muscular Dystrophy
Parkinson's Disease Foundation
PATH (health technologies)
PATH Vaccine Solutions (Vaccine Development
Affiliate of PATH)
Private Paul Allen Family Foundation
Pediatric Brain Tumor Foundation of the US
Pediatric Cancer Foundation
Pediatric Endocrine Society
Pediatric Epilepsy Research Foundation
Pediatric IBD Foundation
Private Perot Foundation
Phase 1
Phelan McDermid Syndrome Foundation
PKD Association
Plastic Surgery Research Foundation
PMP Research Foundation
Preectampsia Foundation
Prevent Cancer Foundation
Progeria Research Foundation
Propionic Acidemia Foundation
Prostate Cancer Foundation
Pulminary Fibrosis Foundation
Pulminary Hypertension Association
Research Down
Research to Prevent Blindness /Endowment Fund
Retina Research Foundation/ Endowment Fund
Retinoblastoma International
Rett Syndrome Research Trust
Private Richard M. Schulze Family Foundation (Cancer)
Richard M. Schulze Family Foundation (Diabetes Type
Private 1)
Private Richard M. Schulze Family Foundation (TOTAL)
Private Robert Wood Johnson Foundation (General)
Robert Wood Johnson Foundation (Mental
Private Health/Addiction)
Private Robert Wood Johnson Foundation (Nutrition/Obesity)
Private Robert Wood Johnson Foundation (TOTAL)
Roger Wyburn-Mason & Jack Blount Foundation for
Eradication of Rheumatoid Disease
Private Roy J. Carver Charitable Trust
Private Russeill Berrie Foundation
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$ 13,357,000 $ 175,594,000
$ 3,830,000 $ 1,260,000
$$
$S
110,000 Y
38,126,000 Y
300,000 Y
202,000 $ 250,000 S 180,000
12,092,000
870,000
9,403,000
5,658,000
1,190,000
5,470,000
10,B03,000
9,370,000
98,000
330,000
445,000
1B5,000
528,000
19,687,000
5,776,000
499,000
1,796,000
(1,082,000)
49,564,000
223,000
360,000
22,703,000
51,225,000
1,179,000
2,259,000
18,993,000
1,515,000
106,000
9,637,000
301,000
5,375,000
495,000
3,586,000
1,023,000
1,080,000
7,380,000
15,700,000
789,000
4,251,000
10,047,000
526,000
329,000
601,000
10,428,000
6,953,000
699,000
325,000
3,333,000
352,000
10,300,000
150,000
111,000
13,739,000
13,258,000
114,000
1,624,000
7,437,000
616,000
301,000
12,388,000
101,622,000
1,619,000
4,024,000 Y
160,000 Y
1,512,000
885,000
474,000
2,540,000
61,101,000
4,300,000
781,000
70,000
1,107,000
318,000
185,000
246,000
11,223,000
1,770,000
324,000 Y
125,000
2,037,000
36,000
2,290,000 Y
43,000
95,000
9,100,000 y
9,242,000
97,000
432,000
6,314,000
324,000
104,000
4,000,000
2,690,000
1,594,000
$ 2,848,000 $ 6,220,000 $ 3,797,000 Y
$ 12,049,000 $ 9,518,000 $ 5,700,000
126,817,000
4,941,000
(330,000)
3,278,000
591,000
83,000
1,625,000
$
$
$
$S
$
$S
$S
$S
$S
$
$ 14,283,000 $
$
$
$
$
$
$
$
172,000
494,000
8,570,000
2,794,000
127,000
29,571,000
3,532,000
251,000
$$
$S
$
$
$
$S
$S
$
256,996,000
37,227,000
14,896,000
4,750,000
770,000
1,299,000
568,000
371,000
18,660,000
691,000
17,931,000 Y
37,227,000 Y
1,500,000
2,000,000
422,000
600,000
568,000
300,000
2,000,000
658,000
205,000 $ 10,000
8,308,000 $ 1,000,000 Y
2,622,000 $ 1,083,000
228,000
415,000
5,209,000
1,241,000
38,000
42,561,000
910,000
7,762,000
487,000
212,000
54,000
954,000
775,000
28,000
20,000,000
154,000
465,000
257,000
$ 254,427,000 $ 12,275,000 $ 2,557,000
$ 40,171,000 $ 1,410,000 $ 1,275,000
$ 168,000 $ 46,000 $
$ 380,000 $ 3,855,000 $
$
$
$
$
$S
42,000
3,564,000 Y
4,492,000
8,257,000
12,749,000
8,029,917
3,875,000
$ 7,695,403
$
$
$ 264,564,000 $
$ 212,489,000 $
482,138,046
656,000
15,254,000
15,723,000
23,923,535
42,000
8,100,000
4,000,000
$
$
$
$
Alzheimers, brain disease
Duchenne Muscular
Dystrophy
General, genetics
Spinal injury, Paralysis
Cancer
Sanfilippo Syndrome
Sarcoma
Heart disease, Cardiovascular
Scleroderma
Sceroderma
Longevity, Aging
General
Shwachman-Diamond
Syndrome (SDS)
Cancer
General
Autism
Sjogren's Syndrome
Lupus
Pediactric Cancer
Spinal Muscular Atrophy
Spinal injury/Problems
General, Cancer, Stem Cells,
Preventitive
Cancer
Pediactric Cancer
Pediactric Cancer
Sturge Weber and Associated
Port Wine Marks
Sudden Infant Death
Syndrome
Ovarian Cancer
Cancer
Gastroenterology, Digestive
disease, nutrion, (Pediatric)
General
General
Cancer
Neuromuscular;
Neurodegenerative; ALR
General: Cancer;
Neurodegenerative
Lyme Disease
General: Leukemia; Cancer;
HIV /AIDS;
Tourette Syndrome
Cancer
Breast Cancer (Triple
Negative)
Tuberous Scerlorsis
Dystonia
Ruth K Broad Biomedical Research Foundation
Ryan's Quest
Sage Bionetworks
Sam Schmidt Paralysis Foundation
Samuel Waxman Cancer Research Foundation
Sanfilippo Research Foundation (Ben's Hope)
Sarcoma Research Foundation
Sarnoff Cardiovascular Research Foundation
Scleroderma Research Foundation
Sclerodoma Foundaiton
SENS Foundation, Inc.
Private Sherman Fairchild Foundation
Private
Shwachman Diamond Syndrome Foundation
Sidney Kimmel Cancer Foundation
Silicon Valley Community Foundation
Private Simons Foundation
Sjogren's Syndrome Foundation
SLE Lupus Foundation
Solving Kids Cancer
Private Spinal Muscular Atrophy Foundation
Spinal Research Foundation
Private Starr Foundation
Stop Cancer
Stop Children's Cancer
Strike 3 Foundation
Sturge-Weber Foundation
Sudden Infant Death Syndrome Alliance
Teal Ribbon Ovarian Cancer Research Foundation
Private Termeer Family
The Children's Digestive Health and Nutrition
Foundation
Private The Hartwell Foundation
Private
Private
Private
Operating
The Robert Kravis and Kimberley Kravis Foundation
The Tow Foundation, Inc. (Cancer, other)
The Tow Foundation, Inc. (Neurodegenerative; ALS)
The Tow Foundation, Inc. (TOTAL)
Time for Lyme
TJ Martell Foundation
Tourette Syndrome Association
Translational Oncology Research International
Triple Negative
Tuberous Sclerosis Alliance
Tyler's Hope for a Dystonla Cure, Inc
Lung Cancer United Against Lung Cancer
Mitochondrial Disease United Mitochondrial Disease Foundation
Cancer Vannie E. Cook Jr. Cancer Foundation
Vascular Disease Vascular Cures
Cancer Virginia & D.K. Ludwig Fund For Cancer Research
General: Translational
Genomics Private Virginia G. Piper Charitable Trust
Blindness, Macular
degeneration Vision Research Foundation
General Private Wallace H. Coulter Foundation
Cancer Private Walther Cancer Foundation Inc
General Private Washington Research Foundation
General Private Wayne and Gladys Valley Foundation
General, Integrative medicine Private Well Foundation
General Wellcome Trust
General; Brain Private William K Warren Foundation
General Private William K. Bowes Jr. Foundation
Williams Syndrome Williams Syndrome Association
Pediactric Cancer Wipe Out Kids Cancer
Angelman / Rett Syndromes Private WM Keck Foundation (Angelman/Rett)
Brain, Neurological Private WM Keck Foundation (Brain/Neurological)
Cancer Private WM Keck Foundation (Cancer/Genetics)
General Private WM Keck Foundation (General)
Genomics, Genetics Private WM Keck Foundation (Genomics)
Infectious Disease Private WM Keck Foundation (Infectious Disease)
Liver disease Private WM Keck Foundation (Liver Disease)
Malaria Private WM Keck Foundation (Malaria)
Private WM Keck Foundation (TOTAL)
$ 12,205,000 $ 525,000 $ 504,000
705,000
1,538,000
7,327,000
100,000
221,000
28,109,000
3,275,000
9,486,000
500,000
$S$
$
$
$
$
$
$
$
$
$
112,000 $
1,603,560,000 $
220,000 $
3,821,000 $
909,000 $
4,100,000 $
1,342,702,000
875,000
1,085,000
298,000
$
130,000
4,777,000
508,000
4,584,000
200,000
102,000
1,410,000
1,692,000
4,885,000
1,520,000
40,359,000
108,000
333,666,000
148,000,000
2,056,000
2,916,000
1,192,000
11,260,000
113,000
108,000,000
1,447,000
216,000
199,000
20,000
4,112,000 Y
252,000
3,188,000
200,000 Y
100,000
813,000
1,016,000
1,000,000
940,000
1,200,000
65,000
22,917,000
3,356,000
45,000,000
392,000
226,000
658,000 Y
8,990,268 Y
113,000
30,000,000
850,000
180,000
188,000
307,000 $ 338,000 $ 89,000
$ 2,713,000 $
$ 95,000 $ 135,000 $
$ 2,914,000 $ 1,529,000 $
$ 111,675,000 $ 8,992,000 $
$ 7,096,000 $ 8,316,000 $
400,000
100,000
10,000,000
1,016,000
5,100,000
2,000,000
1,500,000
$ 3,000,000
$ 108,330,000 $ 10,837,000 $ 4,500,000
$ 788,000 $ 290,000 $ 54,000
$ 1,347,000 $ 3,135,000 $ 2,416,000
$ 1,224,000 $ 7,321,000 $ 2,909,000
$ 1,197,000 $ 5,480,000 $ 5,300,000
$S
$
$S
$
$
$
$
436,000
7,752,000
670,000
943,000
916,000
7,822,000
1,497,000
22,458,000
$S
$S
$S
$S
$S
$
$S
$
920,000
3,706,000
311,000
2,451,000
2,563,000
1,088,000
609,000
4,328,000
500,000
1,970,000
306,000 Y
1,280,000
748,000
800,000
354,000
4,200,000
510,887,000 $ 17,999,000 $ 3,000,000
147,000
289,253,000
146,000,000
154,191,000
386,802,000
489,000
23,362,000
195,786,000
1,751,000
128,000
575,000
75,160,000
9,000,000
4,500,000
43,000,000
427,000
1,116,025,000
17,751,000
24,076,000
748,000
719,000
$ 1,167,429,000 $ 52,754,000
568,000
68,268,000
8,000,000
4,000,000
17,500,000
427,000
7,000,000 Y
15,535,000
8,100,000
106,000
500,000
1,000,000
1,000,000
500,000
20,000,000
3,000,000
2,500,000
7,500,000
500,000
36,000,000
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